BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002;36:227-242. [PMID: 12085369 DOI: 10.1053/jhep.2002.34734] [Cited by in Crossref: 406] [Cited by in F6Publishing: 368] [Article Influence: 20.3] [Reference Citation Analysis]
Number Citing Articles
1 Jaurigue MM, Cappell MS. Therapy for alcoholic liver disease. World J Gastroenterol 2014; 20(9): 2143-2158 [PMID: 24605013 DOI: 10.3748/wjg.v20.i9.2143] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
2 Giacalone G, Matoori S, Agostoni V, Forster V, Kabbaj M, Eggenschwiler S, Lussi M, De Gottardi A, Zamboni N, Leroux J. Liposome-supported peritoneal dialysis in the treatment of severe hyperammonemia: An investigation on potential interactions. Journal of Controlled Release 2018;278:57-65. [DOI: 10.1016/j.jconrel.2018.03.030] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
3 Jiang X, Lin D, Shao H, Yang X. Antioxidant properties of Komagataeibacter hansenii CGMCC 3917 and its ameliorative effects on alcohol-induced liver injury in mice. CyTA - Journal of Food 2019;17:355-64. [DOI: 10.1080/19476337.2019.1584647] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Cheung O, Sterling RK, Salvatori J, Williams K, Hubbard S, Luketic VA, Stravitz TR, Sanyal AJ, Contos MJ, Mills S. Mild alcohol consumption is not associated with increased fibrosis in patients with chronic hepatitis C. J Clin Gastroenterol. 2011;45:76-82. [PMID: 20818236 DOI: 10.1097/mcg.0b013e3181e12511] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
5 Assimakopoulos SF, Vagianos CE, Zervoudakis G, Filos KS, Georgiou C, Nikolopoulou V, Scopa CD. Gut regulatory peptides bombesin and neurotensin reduce hepatic oxidative stress and histological alterations in bile duct ligated rats. Regul Pept. 2004;120:185-193. [PMID: 15177937 DOI: 10.1016/j.regpep.2004.03.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
6 Seraj SM, Campbell EJ, Argyropoulos SK, Wegermann K, Chung RT, Richter JM. Hospital readmissions in decompensated cirrhotics: Factors pointing toward a prevention strategy. World J Gastroenterol 2017; 23(37): 6868-6876 [PMID: 29085229 DOI: 10.3748/wjg.v23.i37.6868] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 16] [Article Influence: 5.2] [Reference Citation Analysis]
7 Nyberg SL, Hardin J, Amiot B, Argikar UA, Remmel RP, Rinaldo P. Rapid, large-scale formation of porcine hepatocyte spheroids in a novel spheroid reservoir bioartificial liver. Liver Transpl 2005;11:901-10. [DOI: 10.1002/lt.20446] [Cited by in Crossref: 96] [Cited by in F6Publishing: 91] [Article Influence: 5.6] [Reference Citation Analysis]
8 Lefkowitch JH. Hepatobiliary pathology: . Current Opinion in Gastroenterology 2003;19:185-93. [DOI: 10.1097/00001574-200305000-00002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
9 Talwalkar JA, Yin M, Fidler JL, Sanderson SO, Kamath PS, Ehman RL. Magnetic resonance imaging of hepatic fibrosis: Emerging clinical applications. Hepatology 2008;47:332-42. [DOI: 10.1002/hep.21972] [Cited by in Crossref: 232] [Cited by in F6Publishing: 211] [Article Influence: 15.5] [Reference Citation Analysis]
10 Kanwal F, Hoang T, Kramer J, Chrusciel T, El-Serag H, Dominitz JA, Asch SM. The performance of process measures in hepatitis C. Am J Gastroenterol 2012;107:1512-21. [PMID: 22777337 DOI: 10.1038/ajg.2012.201] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
11 Yang Y, Ji J, Di L, Li J, Hu L, Qiao H, Wang L, Feng Y. Resource, chemical structure and activity of natural polysaccharides against alcoholic liver damages. Carbohydr Polym 2020;241:116355. [PMID: 32507196 DOI: 10.1016/j.carbpol.2020.116355] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
12 Kanwal F, Kramer JR, Buchanan P, Asch SM, Assioun Y, Bacon BR, Li J, El-Serag HB. The quality of care provided to patients with cirrhosis and ascites in the Department of Veterans Affairs. Gastroenterology. 2012;143:70-77. [PMID: 22465432 DOI: 10.1053/j.gastro.2012.03.038] [Cited by in Crossref: 106] [Cited by in F6Publishing: 84] [Article Influence: 10.6] [Reference Citation Analysis]
13 Schlaphoff V, Klade CS, Jilma B, Jelovcan SB, Cornberg M, Tauber E, Manns MP, Wedemeyer H; IC41 Study Group. Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. Vaccine 2007;25:6793-806. [PMID: 17686555 DOI: 10.1016/j.vaccine.2007.06.026] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
14 Corbin IR, Furth EE, Pickup S, Siegelman ES, Delikatny EJ. In vivo assessment of hepatic triglycerides in murine non-alcoholic fatty liver disease using magnetic resonance spectroscopy. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2009;1791:757-63. [DOI: 10.1016/j.bbalip.2009.02.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
15 Lang CA, Conrad S, Garrett L, Battistutta D, Cooksley WG, Dunne MP, Macdonald GA. Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection. J Pain Symptom Manage. 2006;31:335-344. [PMID: 16632081 DOI: 10.1016/j.jpainsymman.2005.08.016] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 3.4] [Reference Citation Analysis]
16 Maassel NL, Fleming MM, Luo J, Zhang Y, Pei KY. Model for End-Stage Liver Disease Sodium as a Predictor of Surgical Risk in Cirrhotic Patients With Ascites. J Surg Res 2020;250:45-52. [PMID: 32018142 DOI: 10.1016/j.jss.2019.12.037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Kanwal F, Gralnek IM, Hays RD, Zeringue A, Durazo F, Han SB, Saab S, Bolus R, Spiegel BM. Health-related quality of life predicts mortality in patients with advanced chronic liver disease. Clin Gastroenterol Hepatol. 2009;7:793-799. [PMID: 19306949 DOI: 10.1016/j.cgh.2009.03.013] [Cited by in Crossref: 87] [Cited by in F6Publishing: 86] [Article Influence: 6.7] [Reference Citation Analysis]
18 Cortez-pinto H, Marques-vidal P, Monteiro E. Liver disease-related admissions in Portugal: clinical and demographic pattern. European Journal of Gastroenterology & Hepatology 2004;16:873-7. [DOI: 10.1097/00042737-200409000-00010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
19 Singal AK, Kamath PS. Acute on chronic liver failure in non-alcoholic fatty liver and alcohol associated liver disease. Transl Gastroenterol Hepatol 2019;4:74. [PMID: 31728431 DOI: 10.21037/tgh.2019.09.11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
20 de Oliveira AC, El-Bacha I, Vianna MV, Parise ER. Utility and limitations of APRI and FIB4 to predict staging in a cohort of nonselected outpatients with hepatitis C. Ann Hepatol. 2016;15:326-332. [PMID: 27049486 DOI: 10.5604/16652681.1198801] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
21 Rockey DC. New therapies in hepatitis C virus and chronic liver disease: antifibrotics. Clin Liver Dis 2006;10:881-900. [PMID: 17164123 DOI: 10.1016/j.cld.2006.08.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
22 Arepally A, Karmarkar PV, Qian D, Barnett B, Atalar E. Evaluation of MR/Fluoroscopy–guided Portosystemic Shunt Creation in a Swine Model. Journal of Vascular and Interventional Radiology 2006;17:1165-73. [DOI: 10.1097/01.rvi.0000228493.07075.fc] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
23 Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR, Dhibar T, Bhattacharya B, Bhattacharya D, Manna B. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology. 2010;51:1593-1602. [PMID: 20222092 DOI: 10.1002/hep.23567] [Cited by in Crossref: 250] [Cited by in F6Publishing: 233] [Article Influence: 20.8] [Reference Citation Analysis]
24 Flemming JA, Dewit Y, Mah JM, Saperia J, Groome PA, Booth CM. Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study. Lancet Gastroenterol Hepatol 2019;4:217-26. [PMID: 30573390 DOI: 10.1016/S2468-1253(18)30339-X] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
25 Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60:715-735. [PMID: 25042402 DOI: 10.1002/hep.27210] [Cited by in Crossref: 879] [Cited by in F6Publishing: 680] [Article Influence: 109.9] [Reference Citation Analysis]
26 Bang HA, Kwon YH, Lee MJ, Lee WC. Trends in the epidemiological aspects and mortality of alcoholic liver disease in Korea in the decade between 2000 and 2009. J Clin Med Res 2015;7:91-6. [PMID: 25436025 DOI: 10.14740/jocmr1975e] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
27 Chung W. The cost of liver disease in Korea: methodology, data, and evidence. Clin Mol Hepatol 2015;21:14-21. [PMID: 25834797 DOI: 10.3350/cmh.2015.21.1.14] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
28 Rockey DC. Hepatic fibrosis, stellate cells, and portal hypertension. Clin Liver Dis. 2006;10:459-479, vii-viii. [PMID: 17162223 DOI: 10.1016/j.cld.2006.08.017] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 5.1] [Reference Citation Analysis]
29 David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology. 2009;49:1904-1912. [PMID: 19434741 DOI: 10.1002/hep.22868] [Cited by in Crossref: 85] [Cited by in F6Publishing: 84] [Article Influence: 6.5] [Reference Citation Analysis]
30 Cao S, Yaqoob U, Das A, Shergill U, Jagavelu K, Huebert RC, Routray C, Abdelmoneim S, Vasdev M, Leof E, Charlton M, Watts RJ, Mukhopadhyay D, Shah VH. Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing PDGF/TGF-beta signaling in hepatic stellate cells. J Clin Invest. 2010;120:2379-2394. [PMID: 20577048 DOI: 10.1172/jci41203] [Cited by in Crossref: 103] [Cited by in F6Publishing: 71] [Article Influence: 8.6] [Reference Citation Analysis]
31 Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallée M, Heaton S, Conrad A, Pockros PJ, McHutchison JG. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol. 2004;40:484-490. [PMID: 15123364 DOI: 10.1016/j.jhep.2003.11.004] [Cited by in Crossref: 273] [Cited by in F6Publishing: 249] [Article Influence: 15.2] [Reference Citation Analysis]
32 Fried MW, Kroner BL, Preiss LR, Wilhelmsen K, Goedert JJ; Multicenter Hemophilia Cohort Study. Hemophilic siblings with chronic hepatitis C: Familial aggregation of spontaneous and treatment-related viral clearance. Gastroenterology 2006;131:757-64. [PMID: 16952545 DOI: 10.1053/j.gastro.2006.07.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
33 Sehgal R, Kaur S, Shasthry SM, Agrawal T, Dwivedi V, Seth D, Ramakrishna G, Sarin SK, Trehanpati N. Natural Killer Cells Contribute to Pathogenesis of Severe Alcoholic Hepatitis by Inducing Lysis of Endothelial Progenitor Cells. Alcohol Clin Exp Res 2020;44:78-86. [PMID: 31746472 DOI: 10.1111/acer.14242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Cheng Y, Zheng H, Wang B, Xu W, Xu J, Zhu Y. Sorafenib and fluvastatin synergistically alleviate hepatic fibrosis via inhibiting the TGFβ1/Smad3 pathway. Dig Liver Dis 2018;50:381-8. [PMID: 29373239 DOI: 10.1016/j.dld.2017.12.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
35 Ghabril M. Improving Outcomes in Critical Care of Patients With Cirrhosis and Organ Failure: Herding Runaway Horses and Securing the Barn Door. Clin Gastroenterol Hepatol 2015;13:1361-3. [PMID: 25681692 DOI: 10.1016/j.cgh.2015.02.004] [Reference Citation Analysis]
36 Duan BW, Lu SC, Wang ML, Liu JN, Chi P, Lai W, Wu JS, Guo QL, Lin DD, Liu Y. Liver transplantation in acute-on-chronic liver failure patients with high model for end-stage liver disease (MELD) scores: a single center experience of 100 consecutive cases. J Surg Res. 2013;183:936-943. [PMID: 23558257 DOI: 10.1016/j.jss.2013.03.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
37 Loomba R, Wesley R, Bain A, Csako G, Pucino F. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. Clin Gastroenterol Hepatol. 2009;7:487-493. [PMID: 19250986 DOI: 10.1016/j.cgh.2008.12.018] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
38 Vong S, Bell BP. Chronic liver disease mortality in the United States, 1990-1998. Hepatology. 2004;39:476-483. [PMID: 14768001 DOI: 10.1002/hep.20049] [Cited by in Crossref: 101] [Cited by in F6Publishing: 97] [Article Influence: 5.6] [Reference Citation Analysis]
39 Rockey DC, Friedman SL. Hepatic Fibrosis and Cirrhosis. Zakim and Boyer's Hepatology. Elsevier; 2006. pp. 87-109. [DOI: 10.1016/b978-1-4160-3258-8.50011-5] [Cited by in Crossref: 8] [Article Influence: 0.5] [Reference Citation Analysis]
40 Buch S, Stickel F, Trépo E, Way M, Herrmann A, Nischalke HD, Brosch M, Rosendahl J, Berg T, Ridinger M. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet. 2015;47:1443-1448. [PMID: 26482880 DOI: 10.1038/ng.3417] [Cited by in Crossref: 252] [Cited by in F6Publishing: 228] [Article Influence: 36.0] [Reference Citation Analysis]
41 Park MS, Hong S, Lim YL, Kang SH, Baik SK, Kim MY. Measuring Intrahepatic Vascular Changes Using Contrast-Enhanced Ultrasonography to Predict the Prognosis of Alcoholic Hepatitis Combined with Cirrhosis: A Prospective Pilot Study. Gut Liver 2018;12:555-61. [PMID: 29699059 DOI: 10.5009/gnl17342] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
42 Sclair SN, Carrasquillo O, Czul F, Trivella JP, Li H, Jeffers L, Martin P. Quality of Care Provided by Hepatologists to Patients with Cirrhosis at Three Parallel Health Systems. Dig Dis Sci 2016;61:2857-67. [PMID: 27289585 DOI: 10.1007/s10620-016-4221-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
43 Bajaj JS, Saeian K, Christensen KM, Hafeezullah M, Varma RR, Franco J, Pleuss JA, Krakower G, Hoffmann RG, Binion DG. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol. 2008;103:1707-1715. [PMID: 18691193 DOI: 10.1111/j.1572-0241.2008.01861.x] [Cited by in Crossref: 182] [Cited by in F6Publishing: 162] [Article Influence: 13.0] [Reference Citation Analysis]
44 Stief JD, Haase M, Lüdemann L, Theilig D, Schmelzle M, Hamm B, Denecke T, Geisel D. Combined morphological and functional liver MRI using spin-lattice relaxation in the rotating frame (T1ρ) in conjunction with Gadoxetic Acid-enhanced MRI. Sci Rep 2019;9:2083. [PMID: 30765741 DOI: 10.1038/s41598-018-37689-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
45 John JA, de Mattos AA, da Silva Miozzo SA, Comerlato PH, Porto M, Contiero P, da Silva RR. Survival and risk factors related to death in outpatients with cirrhosis treated in a clinic in Southern Brazil. Eur J Gastroenterol Hepatol. 2015;27:1372-1377. [PMID: 26426832 DOI: 10.1097/meg.0000000000000480] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
46 Kim NH, Heo JD, Rho JR, Yang MH, Jeong EJ. The Standardized Extract of Limonium tetragonum Alleviates Chronic Alcoholic Liver Injury in C57Bl/6J Mice. Pharmacogn Mag 2018;14:58-63. [PMID: 29576702 DOI: 10.4103/pm.pm_44_17] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Spiewak T, Taefi A, Patel S, Li CS, Chak E. Racial disparities of Black Americans hospitalized for decompensated liver cirrhosis. BMC Gastroenterol. 2020;20:245. [PMID: 32727386 DOI: 10.1186/s12876-020-01392-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
48 Mills SJ, Harrison SA. Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease. Curr Gastroenterol Rep. 2005;7:32-36. [PMID: 15701296 DOI: 10.1007/s11894-005-0063-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
49 Asrani SK, Kim WR, Kamath PS. Race and receipt of liver transplantation: location matters. Liver Transpl 2010;16:1009-12. [PMID: 20818737 DOI: 10.1002/lt.22123] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
50 Laleman W, Verbeke L, Meersseman P, Wauters J, van Pelt J, Cassiman D, Wilmer A, Verslype C, Nevens F. Acute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions. Expert Rev Gastroenterol Hepatol. 2011;5:523-537; quiz 537. [PMID: 21780899 DOI: 10.1586/egh.11.47] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 6.0] [Reference Citation Analysis]
51 Allen AM, Hay JE. Review article: the management of cirrhosis in women. Aliment Pharmacol Ther 2014;40:1146-54. [PMID: 25263269 DOI: 10.1111/apt.12974] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
52 Yang ZJ, Costa KA, Novelli EM, Smith RE. Venous thromboembolism in cirrhosis. Clin Appl Thromb Hemost 2014;20:169-78. [PMID: 23076776 DOI: 10.1177/1076029612461846] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
53 Hatanaka K, Kudo M, Fukunaga T, Ueshima K, Chung H, Minami Y, Sakaguchi Y, Hagiwara S, Orino A, Osaki Y. Clinical characteristics of NonBNonC- HCC: Comparison with HBV and HCV related HCC. Intervirology. 2007;50:24-31. [PMID: 17164554 DOI: 10.1159/000096309] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
54 Han SH, Suk KT, Kim DJ, Kim MY, Baik SK, Kim YD, Cheon GJ, Choi DH, Ham YL, Shin DH. Effects of probiotics (cultured Lactobacillus subtilis/Streptococcus faecium) in the treatment of alcoholic hepatitis: randomized-controlled multicenter study. Eur J Gastroenterol Hepatol. 2015;27:1300-1306. [PMID: 26302024 DOI: 10.1097/meg.0000000000000458] [Cited by in Crossref: 49] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
55 Hu EA, Lazo M, Selvin E, Hamilton JP, Grams ME, Steffen LM, Coresh J, Rebholz CM. Coffee consumption and liver-related hospitalizations and deaths in the ARIC study. Eur J Clin Nutr 2019;73:1133-40. [PMID: 30341433 DOI: 10.1038/s41430-018-0346-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
56 Cui R, Yan L, Luo Z, Guo X, Yan M. Blockade of store-operated calcium entry alleviates ethanol-induced hepatotoxicity via inhibiting apoptosis. Toxicology and Applied Pharmacology 2015;287:52-66. [DOI: 10.1016/j.taap.2015.05.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
57 Poovorawan K, Treeprasertsuk S, Thepsuthammarat K, Wilairatana P, Kitsahawong B, Phaosawasdi K. The burden of cirrhosis and impact of universal coverage public health care system in Thailand: Nationwide study. Ann Hepatol 2015;14:862-8. [PMID: 26436358 DOI: 10.5604/16652681.1171773] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
58 Canbay A, Feldstein A, Baskin-Bey E, Bronk SF, Gores GJ. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther. 2004;308:1191-1196. [PMID: 14617689 DOI: 10.1124/jpet.103.060129] [Cited by in Crossref: 158] [Cited by in F6Publishing: 146] [Article Influence: 8.3] [Reference Citation Analysis]
59 Chiang DJ, McCullough AJ. The impact of obesity and metabolic syndrome on alcoholic liver disease. Clin Liver Dis. 2014;18:157-163. [PMID: 24274871 DOI: 10.1016/j.cld.2013.09.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
60 Ray S, Khanra D, Sonthalia N, Kundu S, Biswas K, Talukdar A, Saha M, Bera H. Clinico-biochemical correlation to histological findings in alcoholic liver disease: a single centre study from eastern India. J Clin Diagn Res 2014;8:MC01-5. [PMID: 25478382 DOI: 10.7860/JCDR/2014/8763.4968] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
61 Bush H, Golabi P, Otgonsuren M, Rafiq N, Venkatesan C, Younossi ZM. Nonalcoholic Fatty Liver is Contributing to the Increase in Cases of Liver Disease in US Emergency Departments. J Clin Gastroenterol 2019;53:58-64. [PMID: 29608451 DOI: 10.1097/MCG.0000000000001026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
62 Zhang L, Zhou X, Dai Y, Lv C, Wu J, Wu Q, Li T, Wang Y, Xia P, Pei H, Huang B. Establishment of interleukin-18 time-resolved fluorescence immunoassay and its preliminary application in liver disease. J Clin Lab Anal 2021;35:e23758. [PMID: 33720453 DOI: 10.1002/jcla.23758] [Reference Citation Analysis]
63 Méndez-sánchez N, Almeda-valdés P, Uribe M. Alcoholic liver disease. An update. Annals of Hepatology 2005;4:32-42. [DOI: 10.1016/s1665-2681(19)32083-6] [Cited by in Crossref: 21] [Article Influence: 1.2] [Reference Citation Analysis]
64 Nedredal GI, Yin M, McKenzie T, Lillegard J, Luebke-Wheeler J, Talwalkar J, Ehman R, Nyberg SL. Portal hypertension correlates with splenic stiffness as measured with MR elastography. J Magn Reson Imaging 2011;34:79-87. [PMID: 21608066 DOI: 10.1002/jmri.22610] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 7.3] [Reference Citation Analysis]
65 Teegen EM, Krebs I, Langelotz C, Pratschke J, Rau B. Gender Mainstreaming and Transplant Surgery. Visc Med 2016;32:286-9. [PMID: 27722166 DOI: 10.1159/000446357] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
66 M. Brunt E, G. Tiniakos D. Fatty Liver Disease. Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. Elsevier; 2009. pp. 1087-114. [DOI: 10.1016/b978-141604059-0.50044-8] [Cited by in Crossref: 8] [Article Influence: 0.6] [Reference Citation Analysis]
67 McIntosh MB, Corner SM, Amiot BP, Nyberg SL. Engineering analysis and development of the spheroid reservoir bioartificial liver. Annu Int Conf IEEE Eng Med Biol Soc 2009;2009:5985-8. [PMID: 19965068 DOI: 10.1109/IEMBS.2009.5334687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
68 Suk KT, Kim MY, Baik SK. Alcoholic liver disease: Treatment. World J Gastroenterol 2014; 20(36): 12934-12944 [PMID: 25278689 DOI: 10.3748/wjg.v20.i36.12934] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
69 von Montfort C, Beier JI, Kaiser JP, Guo L, Joshi-Barve S, Pritchard MT, States JC, Arteel GE. PAI-1 plays a protective role in CCl4-induced hepatic fibrosis in mice: role of hepatocyte division. Am J Physiol Gastrointest Liver Physiol 2010;298:G657-66. [PMID: 20203062 DOI: 10.1152/ajpgi.00107.2009] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
70 Kanwal F, El-Serag H. Improving quality of care in patients with cirrhosis. Clin Liver Dis (Hoboken) 2013;2:123-4. [PMID: 30992842 DOI: 10.1002/cld.189] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
71 Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006;130:231-264; quiz 214-217. [PMID: 16401486 DOI: 10.1053/j.gastro.2005.11.010] [Cited by in Crossref: 261] [Cited by in F6Publishing: 246] [Article Influence: 16.3] [Reference Citation Analysis]
72 Lange PA, Samson CM, Bird MA, Hayden MA, Behrns KE. Cirrhotic hepatocytes exhibit decreased TGFβ growth inhibition associated with downregulated Smad protein expression. Biochemical and Biophysical Research Communications 2004;313:546-51. [DOI: 10.1016/j.bbrc.2003.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
73 Gehrau R, Mas V, Archer K, Maluf D. Biomarkers of disease differentiation: HCV recurrence versus acute cellular rejection. Fibrogenesis Tissue Repair 2012;5:S11. [PMID: 23259646 DOI: 10.1186/1755-1536-5-S1-S11] [Reference Citation Analysis]
74 Voigt MD. Alcohol in hepatocellular cancer. Clin Liver Dis. 2005;9:151-169. [PMID: 15763234 DOI: 10.1016/j.cld.2004.10.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 3.1] [Reference Citation Analysis]
75 Rubin JB, Sundaram V, Lai JC. Gender Differences Among Patients Hospitalized With Cirrhosis in the United States. J Clin Gastroenterol 2020;54:83-9. [PMID: 30807399 DOI: 10.1097/MCG.0000000000001192] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
76 Serper M, Kaplan DE, Shults J, Reese PP, Beste LA, Taddei TH, Werner RM. Quality Measures, All-Cause Mortality, and Health Care Use in a National Cohort of Veterans With Cirrhosis. Hepatology 2019;70:2062-74. [PMID: 31107967 DOI: 10.1002/hep.30779] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
77 Vitor S, Marinho RT, Gíria J, Velosa J. An observational study of the direct costs related to hospital admissions, mortality and premature death associated with liver disease in Portugal. BMC Res Notes 2016;9:62. [PMID: 26843372 DOI: 10.1186/s13104-016-1879-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
78 Higginbotham KB, Lozano R, Brown T, Patt YZ, Arima T, Abbruzzese JL, Thomas MB. A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008;134:1325-1335. [PMID: 18504614 DOI: 10.1007/s00432-008-0406-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
79 Wu C, Yang YX, Bai YQ, Zhang LD. Clinical significance of detection of plasma CDK5 in patients with hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2014; 22(11): 1518-1524 [DOI: 10.11569/wcjd.v22.i11.1518] [Reference Citation Analysis]
80 Taylor RM, Davern T, Munoz S, Han SH, McGuire B, Larson AM, Hynan L, Lee WM, Fontana RJ;  US Acute Liver Failure Study Group. Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. Hepatology. 2006;44:1589-1597. [PMID: 17133489 DOI: 10.1002/hep.21439] [Cited by in Crossref: 136] [Cited by in F6Publishing: 90] [Article Influence: 9.1] [Reference Citation Analysis]
81 Petrasek J, Csak T, Ganz M, Szabo G. Differences in innate immune signaling between alcoholic and non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2013;28 Suppl 1:93-8. [PMID: 23855302 DOI: 10.1111/jgh.12020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
82 Czaja AJ. Autoimmune liver disease: . Current Opinion in Gastroenterology 2003;19:232-42. [DOI: 10.1097/00001574-200305000-00006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
83 Johnson KB, Campbell EJ, Chi H, Zheng H, King LY, Wu Y, Delemos A, Hurairah A, Corey K, Richter JM. Advanced disease, diuretic use, and marital status predict hospital admissions in an ambulatory cirrhosis cohort. Dig Dis Sci. 2014;59:174-182. [PMID: 23990035 DOI: 10.1007/s10620-013-2832-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
84 Smorodinsky E, Ansdell DS, Foster ZW, Mazhar SM, Cruite I, Wolfson T, Sugay SB, Iussich G, Shiehmorteza M, Kono Y, Kuo A, Sirlin CB. Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents. J Magn Reson Imaging 2015;41:1259-67. [PMID: 24811860 DOI: 10.1002/jmri.24650] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
85 Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, Brosgart CL. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009;137:1680-1686. [PMID: 19632234 DOI: 10.53/j.gastro.2009.07.047] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
86 Liu LU, Bodian CA, Gondolesi GE, Schwartz ME, Emre S, Roayaie S, Schiano TD. Marked Differences in acute cellular rejection rates between living-donor and deceased-donor liver transplant recipients. Transplantation. 2005;80:1072-1080. [PMID: 16278588 DOI: 10.1097/01.tp.0000176483.52769.5a] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
87 Marinho RT, Giria J, Moura MC. Rising costs and hospital admissions for hepatocellular carcinoma in Portugal (1993-2005). World J Gastroenterol 2007; 13(10): 1522-1527 [PMID: 17461443 DOI: 10.3748/wjg.v13.i10.1522] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
88 Sypsa V, Touloumi G, Papatheodoridis GV, Tassopoulos NC, Ketikoglou I, Vafiadis I, Hatzis G, Tsantoulas D, Akriviadis E, Koutsounas S, Hatzakis A. Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. J Viral Hepat 2005;12:543-50. [DOI: 10.1111/j.1365-2893.2005.00588.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
89 Bajaj JS, Wade JB, Gibson DP, Heuman DM, Thacker LR, Sterling RK, Stravitz RT, Luketic V, Fuchs M, White MB, Bell DE, Gilles H, Morton K, Noble N, Puri P, Sanyal AJ. The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol. 2011;106:1646-1653. [PMID: 21556040 DOI: 10.1038/ajg.2011.157] [Cited by in Crossref: 201] [Cited by in F6Publishing: 173] [Article Influence: 18.3] [Reference Citation Analysis]
90 Méndez-sánchez N, García-villegas E, Merino-zeferino B, Ochoa-cruz S, Villa AR, Madrigal H, Kobashi-margáin RA, Gutiérrez-grobe Y, Chávez-tapia N, Ponciano-rodríguez G, Uribe M. Liver diseases in Mexico and their associated mortality trends from 2000 to 2007: A retrospective study of the nation and the federal states. Annals of Hepatology 2010;9:428-38. [DOI: 10.1016/s1665-2681(19)31619-9] [Cited by in Crossref: 19] [Article Influence: 1.6] [Reference Citation Analysis]
91 El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27-S34. [PMID: 15508094 DOI: 10.1053/j.gastro.2004.09.013] [Cited by in Crossref: 718] [Cited by in F6Publishing: 662] [Article Influence: 39.9] [Reference Citation Analysis]
92 Kirpich IA, Solovieva NV, Leikhter SN, Shidakova NA, Lebedeva OV, Sidorov PI, Bazhukova TA, Soloviev AG, Barve SS, McClain CJ, Cave M. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol. 2008;42:675-682. [PMID: 19038698 DOI: 10.1016/j.alcohol.2008.08.006] [Cited by in Crossref: 252] [Cited by in F6Publishing: 238] [Article Influence: 19.4] [Reference Citation Analysis]
93 Hayashi PH, Harrison SA, Torgerson S, Perez TA, Nochajski T, Russell M. Cognitive Lifetime Drinking History in Nonalcoholic Fatty Liver Disease: Some Cases May Be Alcohol Related. Am J Gastroenterol 2004;99:76-81. [DOI: 10.1046/j.1572-0241.2003.04013.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.4] [Reference Citation Analysis]
94 Solà E, Solé C, Simón-talero M, Martín-llahí M, Castellote J, Garcia-martínez R, Moreira R, Torrens M, Márquez F, Fabrellas N, de Prada G, Huelin P, Lopez Benaiges E, Ventura M, Manríquez M, Nazar A, Ariza X, Suñé P, Graupera I, Pose E, Colmenero J, Pavesi M, Guevara M, Navasa M, Xiol X, Córdoba J, Vargas V, Ginès P. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. Journal of Hepatology 2018;69:1250-9. [DOI: 10.1016/j.jhep.2018.08.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 39] [Article Influence: 13.0] [Reference Citation Analysis]
95 Choi Y, Abdelmegeed MA, Song BJ. Preventive effects of indole-3-carbinol against alcohol-induced liver injury in mice via antioxidant, anti-inflammatory, and anti-apoptotic mechanisms: Role of gut-liver-adipose tissue axis. J Nutr Biochem 2018;55:12-25. [PMID: 29331880 DOI: 10.1016/j.jnutbio.2017.11.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
96 Mengshol JA, Golden-Mason L, Arikawa T, Smith M, Niki T, McWilliams R, Randall JA, McMahan R, Zimmerman MA, Rangachari M. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One. 2010;5:e9504. [PMID: 20209097 DOI: 10.1371/journal.pone.0009504] [Cited by in Crossref: 115] [Cited by in F6Publishing: 132] [Article Influence: 9.6] [Reference Citation Analysis]
97 Yedibela S, Demir R, Melling N, Aydin Ü, Schuppan D, Müller V, Hohenberger W, Schönleben F. Antiviral re-treatment of IFN-Ribavirin non-responders for recurrent post-transplantation hepatitis C: Re-treatment of non-responders for HCV after OLT. Clinical Transplantation 2011;25:131-5. [DOI: 10.1111/j.1399-0012.2009.01201.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
98 Méndez-sánchez N, Villa AR, Chávez-tapia NC, Ponciano-rodriguez G, Almeda-valdés P, González D, Uribe M. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Annals of Hepatology 2005;4:52-5. [DOI: 10.1016/s1665-2681(19)32086-1] [Cited by in Crossref: 59] [Article Influence: 3.5] [Reference Citation Analysis]
99 Ghosh N, Ghosh R, Mandal V, Mandal SC. Recent advances in herbal medicine for treatment of liver diseases. Pharm Biol. 2011;49:970-988. [PMID: 21595500 DOI: 10.3109/13880209.2011.558515] [Cited by in Crossref: 60] [Cited by in F6Publishing: 47] [Article Influence: 5.5] [Reference Citation Analysis]
100 Goldberg D, Lewis J, Halpern S, Weiner M, Lo Re V 3rd. Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database. Pharmacoepidemiol Drug Saf 2012;21:765-9. [PMID: 22674685 DOI: 10.1002/pds.3290] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 9.3] [Reference Citation Analysis]
101 Mumtaz K, Issak A, Porter K, Kelly S, Hanje J, Michaels AJ, Conteh LF, El-Hinnawi A, Black SM, Abougergi MS. Validation of Risk Score in Predicting Early Readmissions in Decompensated Cirrhotic Patients: A Model Based on the Administrative Database. Hepatology 2019;70:630-9. [PMID: 30218583 DOI: 10.1002/hep.30274] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
102 Shaheen AA, Nguyen HH, Congly SE, Kaplan GG, Swain MG. Nationwide estimates and risk factors of hospital readmission in patients with cirrhosis in the United States. Liver Int. 2019;39:878-884. [PMID: 30688401 DOI: 10.1111/liv.14054] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
103 Udompap P, Kim D, Kim WR. Current and Future Burden of Chronic Nonmalignant Liver Disease. Clin Gastroenterol Hepatol. 2015;13:2031-2041. [PMID: 26291665 DOI: 10.1016/j.cgh.2015.08.015] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 9.9] [Reference Citation Analysis]
104 Wang L, Fouts DE, Stärkel P, Hartmann P, Chen P, Llorente C, DePew J, Moncera K, Ho SB, Brenner DA, Hooper LV, Schnabl B. Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing Mucosa-Associated Microbiota and Preventing Bacterial Translocation. Cell Host Microbe 2016;19:227-39. [PMID: 26867181 DOI: 10.1016/j.chom.2016.01.003] [Cited by in Crossref: 169] [Cited by in F6Publishing: 161] [Article Influence: 28.2] [Reference Citation Analysis]
105 Guerrero JA, Teruel R, Martínez C, Arcas I, Martínez-Martínez I, de la Morena-Barrio ME, Vicente V, Corral J. Protective role of antithrombin in mouse models of liver injury. J Hepatol 2012;57:980-6. [PMID: 22749941 DOI: 10.1016/j.jhep.2012.06.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
106 Rongey C, Kaplowitz N. Current concepts and controversies in the treatment of alcoholic hepatitis. World J Gastroenterol 2006; 12(43): 6909-6921 [PMID: 17109510 DOI: 10.3748/wjg.v12.i43.6909] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
107 Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR. Underestimation of liver-related mortality in the United States. Gastroenterology. 2013;145:375-382.e1-2. [PMID: 23583430 DOI: 10.1053/j.gastro.2013.04.005] [Cited by in Crossref: 172] [Cited by in F6Publishing: 161] [Article Influence: 19.1] [Reference Citation Analysis]
108 Sturzeneker MC, Ioshii SO, Villela Baroncini LA, Précoma DB. Olmesartan severely weakened the development of NASH in an animal model of hypercholesterolemia. Atherosclerosis 2011;216:97-102. [PMID: 21338989 DOI: 10.1016/j.atherosclerosis.2011.01.047] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
109 Ambrosino P, Tarantino L, Di Minno G, Paternoster M, Graziano V, Petitto M, Nasto A, Di Minno MN. The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis. Thromb Haemost. 2017;117:139-148. [PMID: 27761574 DOI: 10.1160/th16-06-0450] [Cited by in Crossref: 72] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
110 Csikesz NG, Nguyen LN, Tseng JF, Shah SA. Nationwide volume and mortality after elective surgery in cirrhotic patients. J Am Coll Surg. 2009;208:96-103. [PMID: 19228510 DOI: 10.1016/j.jamcollsurg.2008.09.006] [Cited by in Crossref: 119] [Cited by in F6Publishing: 88] [Article Influence: 8.5] [Reference Citation Analysis]
111 Blonski W, Siropaides T, Reddy KR. Coagulopathy in liver disease. Curr Treat Options Gastroenterol 2007;10:464-73. [PMID: 18221607 DOI: 10.1007/s11938-007-0046-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
112 Atiemo K, Ladner DP. Active Education, Keeping It Personal and Making It Easy: A Potential Path to Increasing Donors. Transplantation 2015;99:2448. [PMID: 26356177 DOI: 10.1097/TP.0000000000000898] [Reference Citation Analysis]
113 Ridola L, Cardinale V, Riggio O. The burden of minimal hepatic encephalopathy: From diagnosis to therapeutic strategies. Ann Gastroenterol. 2018;31:151-164. [PMID: 29507462 DOI: 10.20524/aog.2018.0232] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
114 Al-dosari MS. Antioxidant and protective effects of spinach ( Spinacia oleracea L.) leaves against carbon tetrachloride-induced liver injury. Clinical and Experimental Medical Journal 2010;4:129-40. [DOI: 10.1556/cemed.4.2010.1.13] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
115 Boyer TD. Primary prophylaxis for variceal bleeding: are we there yet? Gastroenterology 2005;128:1120-2. [PMID: 15825093 DOI: 10.1053/j.gastro.2005.02.035] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
116 Liu H, Beier JI, Arteel GE, Ramsden CE, Feldstein AE, McClain CJ, Kirpich IA. Transient receptor potential vanilloid 1 gene deficiency ameliorates hepatic injury in a mouse model of chronic binge alcohol-induced alcoholic liver disease. Am J Pathol. 2015;185:43-54. [PMID: 25447051 DOI: 10.1016/j.ajpath.2014.09.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
117 Kogure T, Ueno Y, Kawagishi N, Kanno N, Yamagiwa Y, Fukushima K, Satomi S, Shimosegawa T. The model for end-stage liver disease score is useful for predicting economic outcomes in adult cases of living donor liver transplantation. J Gastroenterol 2006;41:1005-10. [PMID: 17096070 DOI: 10.1007/s00535-006-1887-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
118 Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R, Margreiter R, Vogel W. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2007;13:272-279. [PMID: 17256758 DOI: 10.1002/lt.21033] [Cited by in Crossref: 183] [Cited by in F6Publishing: 156] [Article Influence: 12.2] [Reference Citation Analysis]
119 Nuthalapati A, Schluterman N, Khanna A, Greenberg D, Thuluvath PJ. Impact of Acute Kidney Injury on Mortality of Patients Hospitalized for Complications of Cirrhosis. J Clin Exp Hepatol 2017;7:290-9. [PMID: 29234192 DOI: 10.1016/j.jceh.2017.05.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
120 Zhang F, Lee J, Liang S, Shum CK. Cyanobacteria blooms and non-alcoholic liver disease: evidence from a county level ecological study in the United States. Environ Health 2015;14:41. [PMID: 25948281 DOI: 10.1186/s12940-015-0026-7] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
121 Rodriguez-luna H, Vargas HE. Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transpl 2005;11:479-89. [DOI: 10.1002/lt.20424] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
122 Hudson B, Round J, Georgeson B, Pring A, Forbes K, Mccune CA, Verne J. Cirrhosis with ascites in the last year of life: a nationwide analysis of factors shaping costs, health-care use, and place of death in England. The Lancet Gastroenterology & Hepatology 2018;3:95-103. [DOI: 10.1016/s2468-1253(17)30362-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
123 Axley P, Ahmed Z, Arora S, Haas A, Kuo YF, Kamath PS, Singal AK. NASH Is the Most Rapidly Growing Etiology for Acute-on-Chronic Liver Failure-Related Hospitalization and Disease Burden in the United States: A Population-Based Study. Liver Transpl. 2019;25:695-705. [PMID: 30861321 DOI: 10.1002/lt.25443] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
124 Cannon NA, Donlin MJ, Fan X, Aurora R, Tavis JE; Virahep-C Study Group. Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy. PLoS One 2008;3:e2123. [PMID: 18463735 DOI: 10.1371/journal.pone.0002123] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
125 Lahmek P, Meunier N, Michel L, Aubin H, Balester-mouret S. Utilisation de l’élastométrie hépatique comme outil de dépistage de la fibrose hépatique dans un service d’addictologie. La Presse Médicale 2014;43:e17-31. [DOI: 10.1016/j.lpm.2013.07.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
126 Ungrin MD, Clarke G, Yin T, Niebrugge S, Nostro MC, Sarangi F, Wood G, Keller G, Zandstra PW. Rational bioprocess design for human pluripotent stem cell expansion and endoderm differentiation based on cellular dynamics. Biotechnol Bioeng 2012;109:853-66. [PMID: 22139975 DOI: 10.1002/bit.24375] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
127 Birerdinc A, Younossi ZM. Emerging therapies for hepatitis C virus. Expert Opin Emerg Drugs 2010;15:535-44. [PMID: 20629602 DOI: 10.1517/14728214.2010.502527] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
128 Kahloon A, Chalasani N, DeWitt J, Liangpunsakul S, Vinayek R, Vuppalanchi R, Ghabril M, Chiorean M. Endoscopic therapy with 2-octyl-cyanoacrylate for the treatment of gastric varices. Dig Dis Sci. 2014;59:2178-2183. [PMID: 24788319 DOI: 10.1007/s10620-014-3148-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
129 Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, Brancati FL, Clark JM. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013;178:38-45. [PMID: 23703888 DOI: 10.1093/aje/kws448] [Cited by in Crossref: 506] [Cited by in F6Publishing: 471] [Article Influence: 56.2] [Reference Citation Analysis]
130 Trauner M, Boyer JL. Cholestatic syndromes: . Current Opinion in Gastroenterology 2003;19:216-31. [DOI: 10.1097/00001574-200305000-00005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
131 Shiffman ML, Rockey DC. Role and support for hepatologists at liver transplant programs in the United States. Liver Transpl 2008;14:1092-9. [PMID: 18668665 DOI: 10.1002/lt.21523] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
132 Talwalkar JA. Determining the extent of quality health care for hospitalized patients with cirrhosis. Hepatology. 2005;42:492-494. [PMID: 15942950 DOI: 10.1002/hep.20753] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
133 Rodriguez-Luna H, Douglas DD. Natural history of hepatitis C following liver transplantation. Curr Opin Infect Dis. 2004;17:363-371. [PMID: 15241083 DOI: 10.1097/01.qco.0000136934.06039.01] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
134 Reindollar RW, Roberts H. Financial viability of a hepatology practice. Clin Liver Dis (Hoboken) 2017;10:1-3. [PMID: 30992749 DOI: 10.1002/cld.640] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
135 Bosoi CR, Rose CF. Elevated cerebral lactate: Implications in the pathogenesis of hepatic encephalopathy. Metab Brain Dis 2014;29:919-25. [PMID: 24916505 DOI: 10.1007/s11011-014-9573-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
136 Cassidy JW. Nanotechnology in the Regeneration of Complex Tissues. Bone Tissue Regen Insights 2014;5:25-35. [PMID: 26097381 DOI: 10.4137/BTRI.S12331] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
137 Harrison MF. The Misunderstood Coagulopathy of Liver Disease: A Review for the Acute Setting. West J Emerg Med. 2018;19:863-871. [PMID: 30202500 DOI: 10.5811/westjem.2018.7.37893] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
138 Yoon S, Koh E, Kim C, Zee O, Kwak J, Jeong W, Kim J, Lee S. Agrimonia eupatoria protects against chronic ethanol-induced liver injury in rats. Food and Chemical Toxicology 2012;50:2335-41. [DOI: 10.1016/j.fct.2012.04.005] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
139 Li X, Mo N, Li Z. Ginsenosides: potential therapeutic source for fibrosis-associated human diseases. J Ginseng Res 2020;44:386-98. [PMID: 32372860 DOI: 10.1016/j.jgr.2019.12.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
140 Gallegos-Orozco JF, Vargas HE. Liver transplantation: from Child to MELD. Med Clin North Am. 2009;93:931-950, ix. [PMID: 19577123 DOI: 10.1016/j.mcna.2009.03.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
141 Kuo CH, Juang JH, Peng HL. Coculture of hepatocytes with islets. Transplant Proc 2011;43:3167-70. [PMID: 22099747 DOI: 10.1016/j.transproceed.2011.09.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
142 Frazier TH, Stocker AM, Kershner NA, Marsano LS, McClain CJ. Treatment of alcoholic liver disease. Therap Adv Gastroenterol. 2011;4:63-81. [PMID: 21317995 DOI: 10.1177/1756283x10378925] [Cited by in Crossref: 84] [Cited by in F6Publishing: 48] [Article Influence: 7.6] [Reference Citation Analysis]
143 McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, Dore G, Gane E, Guan R, Hamid SS. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol. 2007;22:615-633. [PMID: 17444847 DOI: 10.1111/j.1440-1746.2007.04883.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 111] [Article Influence: 7.4] [Reference Citation Analysis]
144 Silveira MG, Suzuki A, Lindor KD. Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology 2008;48:1149-56. [DOI: 10.1002/hep.22458] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
145 Kasuya J, Tanishita K. Microporous membrane-based liver tissue engineering for the reconstruction of three-dimensional functional liver tissues in vitro. Biomatter 2012;2:290-5. [PMID: 23507893 DOI: 10.4161/biom.22481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
146 Cohen SM, Gundlapalli S, Shah AR, Johnson TJ, Rechner JA, Jensen DM. The downstream financial effect of hepatology. Hepatology 2005;41:968-75. [DOI: 10.1002/hep.20690] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
147 Wu FL, Shi KQ, Chen YP, Braddock M, Zou H, Zheng MH. Scoring systems predict the prognosis of acute-on-chronic hepatitis B liver failure: an evidence-based review. Expert Rev Gastroenterol Hepatol 2014;8:623-32. [PMID: 24762209 DOI: 10.1586/17474124.2014.906899] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
148 Le Strat Y, Le Foll B, Dubertret C. Major depression and suicide attempts in patients with liver disease in the United States. Liver Int 2015;35:1910-6. [PMID: 24905236 DOI: 10.1111/liv.12612] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
149 Dufour DR. Liver Disease. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Elsevier; 2012. pp. 1637-93. [DOI: 10.1016/b978-1-4160-6164-9.00050-0] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
150 Laleman W, Wilmer A, Evenepoel P, Verslype C, Fevery J, Nevens F. Review article: non-biological liver support in liver failure. Aliment Pharmacol Ther. 2006;23:351-363. [PMID: 16422994 DOI: 10.1111/j.1365-2036.2006.02765.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
151 Kim WR. Epidemiology of hepatitis B in the United States. Hepatology 2009;49:S28-34. [PMID: 19399791 DOI: 10.1002/hep.22975] [Cited by in Crossref: 131] [Cited by in F6Publishing: 122] [Article Influence: 10.1] [Reference Citation Analysis]
152 Petitclerc L, Sebastiani G, Gilbert G, Cloutier G, Tang A. Liver fibrosis: Review of current imaging and MRI quantification techniques. J Magn Reson Imaging. 2017;45:1276-1295. [PMID: 27981751 DOI: 10.1002/jmri.25550] [Cited by in Crossref: 89] [Cited by in F6Publishing: 78] [Article Influence: 14.8] [Reference Citation Analysis]
153 Szalowska E, Stoopen G, Groot MJ, Hendriksen PJ, Peijnenburg AA. Treatment of mouse liver slices with cholestatic hepatotoxicants results in down-regulation of Fxr and its target genes. BMC Med Genomics 2013;6:39. [PMID: 24112857 DOI: 10.1186/1755-8794-6-39] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
154 Dolganiuc A, Norkina O, Kodys K, Catalano D, Bakis G, Marshall C, Mandrekar P, Szabo G. Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection. Gastroenterology. 2007;133:1627-1636. [PMID: 17916356 DOI: 10.1053/j.gastro.2007.08.003] [Cited by in Crossref: 142] [Cited by in F6Publishing: 143] [Article Influence: 9.5] [Reference Citation Analysis]
155 Canbay A, Guicciardi ME, Higuchi H, Feldstein A, Bronk SF, Rydzewski R, Taniai M, Gores GJ. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest. 2003;112:152-159. [PMID: 12865404 DOI: 10.1172/jci17740] [Cited by in Crossref: 4] [Cited by in F6Publishing: 66] [Article Influence: 0.2] [Reference Citation Analysis]
156 Mohammed OK, Mahadeva S. Clinical outcomes of cryptogenic compared with non-cryptogenic cirrhosis: A retrospective cohort study. J Gastroenterol Hepatol. 2015;30:1423-1428. [PMID: 25867030 DOI: 10.1111/jgh.12978] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
157 Finzi L, Barbu V, Burgel PR, Mergey M, Kirkwood KS, Wick EC, Scoazec JY, Peschaud F, Paye F, Nadel JA, Housset C. MUC5AC, a gel-forming mucin accumulating in gallstone disease, is overproduced via an epidermal growth factor receptor pathway in the human gallbladder. Am J Pathol 2006;169:2031-41. [PMID: 17148666 DOI: 10.2353/ajpath.2006.060146] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
158 Dávalos Moscol M, Bustios Sanchez C. The burden of hepatic encephalopathy in Latin America. Annals of Hepatology 2011;10:S31-5. [DOI: 10.1016/s1665-2681(19)31603-5] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
159 Puljic A, Salati J, Doss A, Caughey AB. Outcomes of pregnancies complicated by liver cirrhosis, portal hypertension, or esophageal varices. The Journal of Maternal-Fetal & Neonatal Medicine 2015;29:506-9. [DOI: 10.3109/14767058.2015.1009438] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
160 Gaetano JN, Micic D, Aronsohn A, Reddy G, Te H, Reau NS, Jensen D. The benefit of paracentesis on hospitalized adults with cirrhosis and ascites: The benefit of paracentesis. Journal of Gastroenterology and Hepatology 2016;31:1025-30. [DOI: 10.1111/jgh.13255] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
161 Cho Y, Park YS, Kim HY, Kim W, Lee HJ, Kim DJ. Efficacy of granulocyte colony stimulating factor in patients with severe alcoholic hepatitis with partial or null response to steroid (GRACIAH trial): study protocol for a randomized controlled trial. Trials 2018;19:696. [PMID: 30577864 DOI: 10.1186/s13063-018-3092-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
162 Petrasek J, Csak T, Szabo G. Toll-like receptors in liver disease. Adv Clin Chem. 2013;59:155-201. [PMID: 23461136 DOI: 10.1016/b978-0-12-405211-6.00006-1] [Cited by in Crossref: 53] [Cited by in F6Publishing: 32] [Article Influence: 5.9] [Reference Citation Analysis]
163 Stickel F, Buch S, Lau K, zu Schwabedissen HM, Berg T, Ridinger M, Rietschel M, Schafmayer C, Braun F, Hinrichsen H, Günther R, Arlt A, Seeger M, Müller S, Seitz HK, Soyka M, Lerch M, Lammert F, Sarrazin C, Kubitz R, Häussinger D, Hellerbrand C, Bröring D, Schreiber S, Kiefer F, Spanagel R, Mann K, Datz C, Krawczak M, Wodarz N, Völzke H, Hampe J. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology 2011;53:86-95. [DOI: 10.1002/hep.24017] [Cited by in Crossref: 192] [Cited by in F6Publishing: 175] [Article Influence: 16.0] [Reference Citation Analysis]
164 Huu Tung N, Uto T, Morinaga O, Kim YH, Shoyama Y. Pharmacological effects of ginseng on liver functions and diseases: a minireview. Evid Based Complement Alternat Med. 2012;2012:173297. [PMID: 22997528 DOI: 10.1155/2012/173297] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
165 Festi D, Reggiani ML, Attili AF, Loria P, Pazzi P, Scaioli E, Capodicasa S, Romano F, Roda E, Colecchia A. Natural history of gallstone disease: Expectant management or active treatment? J Gastroenterol Hepatol. 2010;25:719-724. [PMID: 20492328 DOI: 10.1111/j.1440-1746.2009.06146.x] [Cited by in Crossref: 96] [Cited by in F6Publishing: 66] [Article Influence: 8.0] [Reference Citation Analysis]
166 Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;32:851-858. [PMID: 20659285 DOI: 10.1111/j.1365-2036.2010.04414.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 7.7] [Reference Citation Analysis]
167 Singal AG, Waljee AK, Shiffman M, Bacon BR, Schoenfeld PS. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Aliment Pharmacol Ther. 2010;32:969-983. [PMID: 20937042 DOI: 10.1111/j.1365-2036.2010.04427.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
168 Santos SGRD, Mattos AA, Guimarães MM, Boger BS, Coral GP. Alcohol Consumption Influences Clinical Outcome in Patients Admitted to a Referral Center for Liver Disease. Ann Hepatol 2018;17:470-5. [PMID: 29735785 DOI: 10.5604/01.3001.0011.7391] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
169 Czaja AJ. Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis. Dig Dis Sci. 2017;62:2277-2292. [PMID: 28710658 DOI: 10.1007/s10620-017-4675-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
170 Wei M, Ford J, Li Q, Jeong D, Kwong AJ, Nguyen MH, Chang MS. Hospital Cirrhosis Volume and Readmission in Patients with Cirrhosis in California. Dig Dis Sci 2018;63:2267-74. [PMID: 29457210 DOI: 10.1007/s10620-018-4964-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
171 Carrion AF, Ghanta R, Carrasquillo O, Martin P. Chronic liver disease in the Hispanic population of the United States. Clin Gastroenterol Hepatol 2011;9:834-41; quiz e109-10. [PMID: 21628000 DOI: 10.1016/j.cgh.2011.04.027] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 5.7] [Reference Citation Analysis]
172 Myers RP, Shaheen AA, Hubbard JN, Kaplan GG. Characteristics of patients with cirrhosis who are discharged from the hospital against medical advice. Clin Gastroenterol Hepatol. 2009;7:786-792. [PMID: 19345284 DOI: 10.1016/j.cgh.2009.03.020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
173 Koola JD, Ho SB, Cao A, Chen G, Perkins AM, Davis SE, Matheny ME. Predicting 30-Day Hospital Readmission Risk in a National Cohort of Patients with Cirrhosis. Dig Dis Sci 2020;65:1003-31. [PMID: 31531817 DOI: 10.1007/s10620-019-05826-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
174 Nielsen J, Nerup N, Møller S, de Nijs R, Rasmussen A, Bo Svendsen L, Kjaer MS, Brix Christensen V, Borgwardt L. Minimally invasive assessment of hepatic function in children with indocyanine green elimination: a validation study. Scandinavian Journal of Gastroenterology 2019;54:485-91. [DOI: 10.1080/00365521.2019.1591497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
175 Axley PD, Richardson CT, Singal AK. Epidemiology of Alcohol Consumption and Societal Burden of Alcoholism and Alcoholic Liver Disease. Clin Liver Dis 2019;23:39-50. [PMID: 30454831 DOI: 10.1016/j.cld.2018.09.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 10.7] [Reference Citation Analysis]
176 Martin DR, Seibert D, Yang M, Salman K, Frick MP. Reversible heterogeneous arterial phase liver perfusion associated with transient acute hepatitis: findings on gadolinium-enhanced MRI. J Magn Reson Imaging 2004;20:838-42. [PMID: 15503331 DOI: 10.1002/jmri.20192] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
177 Agah S, Tavakoli S, Nikbakht H, Najafi M, Al-Agha A. Central venous pressure catheter for large-volume paracentesis in refractory ascites. Indian J Gastroenterol 2014;33:310-5. [PMID: 24756422 DOI: 10.1007/s12664-014-0448-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
178 Firriolo FJ. Dental Management of Patients with End-Stage Liver Disease. Dental Clinics of North America 2006;50:563-90. [DOI: 10.1016/j.cden.2006.06.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
179 Chmielecki DK, Hagopian EJ, Kuo YH, Kuo YL, Davis JM. Laparoscopic cholecystectomy is the preferred approach in cirrhosis: a nationwide, population-based study. HPB (Oxford). 2012;14:848-853. [PMID: 23134187 DOI: 10.1111/j.1477-2574.2012.00562.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
180 Stickel F, Hoehn B, Schuppan D, Seitz HK. Review article: Nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther. 2003;18:357-373. [PMID: 12940921 DOI: 10.1046/j.1365-2036.2003.01660.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 66] [Article Influence: 5.1] [Reference Citation Analysis]
181 Kanwal F, Hoang T, Chrusciel T, Kramer JR, El-Serag HB, Dominitz JA, Asch SM. Process of care for hepatitis C infection is linked to treatment outcome and virologic response. Clin Gastroenterol Hepatol 2012;10:1270-1277.e3. [PMID: 22841970 DOI: 10.1016/j.cgh.2012.07.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
182 American Association for the Study of Liver Diseases. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014;61:642-659. [PMID: 25015420 DOI: 10.1016/j.jhep.2014.05.042] [Cited by in Crossref: 212] [Cited by in F6Publishing: 164] [Article Influence: 26.5] [Reference Citation Analysis]
183 Zhao L, Mehmood A, Yuan D, Usman M, Murtaza MA, Yaqoob S, Wang C. Protective Mechanism of Edible Food Plants against Alcoholic Liver Disease with Special Mention to Polyphenolic Compounds. Nutrients 2021;13:1612. [PMID: 34064981 DOI: 10.3390/nu13051612] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Sutton L, Vusirikala M, Chen W. Hematogone hyperplasia in copper deficiency. Am J Clin Pathol 2009;132:191-9; quiz 307. [PMID: 19605813 DOI: 10.1309/AJCPS3ENUQ5LKBSB] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
185 Tan HH, Virmani S, Martin P. Controversies in the management of alcoholic liver disease. Mt Sinai J Med. 2009;76:484-498. [PMID: 19787655 DOI: 10.1002/msj.20135] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
186 Cheung O, Sanyal AJ. Hepatitis C infection and nonalcoholic fatty liver disease. Clin Liver Dis. 2008;12:573-585, viii-ix. [PMID: 18625429 DOI: 10.1016/j.cld.2008.03.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
187 Shores NJ, Dodge JL, Feng S, Terrault NA. Donor Risk Index for African American liver transplant recipients with hepatitis C virus. Hepatology 2013;58:1263-9. [PMID: 23696235 DOI: 10.1002/hep.26478] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
188 Benarroch-Gampel J, Boyd CA, Sheffield KM, Townsend CM, Riall TS. Overuse of CT in patients with complicated gallstone disease. J Am Coll Surg. 2011;213:524-530. [PMID: 21862355 DOI: 10.1016/j.jamcollsurg.2011.07.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
189 Lopez LJ, Marrero JA. Hepatocellular carcinoma: . Current Opinion in Gastroenterology 2004;20:248-53. [DOI: 10.1097/00001574-200405000-00009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
190 Fagan KJ, Zhao EY, Horsfall LU, Ruffin BJ, Kruger MS, McPhail SM, O'Rourke P, Ballard E, Irvine KM, Powell EE. Burden of decompensated cirrhosis and ascites on hospital services in a tertiary care facility: time for change? Intern Med J. 2014;44:865-872. [PMID: 24893971 DOI: 10.1111/imj.12491] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
191 Stickel F, Osterreicher CH. The role of genetic polymorphisms in alcoholic liver disease. Alcohol Alcohol. 2006;41:209-224. [PMID: 16492723 DOI: 10.1093/alcalc/agl011] [Cited by in Crossref: 84] [Cited by in F6Publishing: 76] [Article Influence: 5.3] [Reference Citation Analysis]
192 Jara M, Bednarsch J, Malinowski M, Lüttgert K, Orr J, Puhl G, Seehofer D, Neuhaus P, Stockmann M. Predictors of quality of life in patients evaluated for liver transplantation. Clin Transplant 2014;28:1331-8. [PMID: 25053350 DOI: 10.1111/ctr.12426] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
193 Ganesh S, Rogal SS, Yadav D, Humar A, Behari J. Risk factors for frequent readmissions and barriers to transplantation in patients with cirrhosis. PLoS One. 2013;8:e55140. [PMID: 23383085 DOI: 10.1371/journal.pone.0055140] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
194 Mejia LM. Oral Manifestations of Gastrointestinal Disorders. Atlas Oral Maxillofac Surg Clin North Am 2017;25:93-104. [PMID: 28778312 DOI: 10.1016/j.cxom.2017.04.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
195 Kanwal F, Spiegel BM, Hays RD, Durazo F, Han SB, Saab S, Bolus R, Kim SJ, Gralnek IM. Prospective validation of the short form liver disease quality of life instrument. Aliment Pharmacol Ther 2008;28:1088-101. [PMID: 18671776 DOI: 10.1111/j.1365-2036.2008.03817.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
196 Czaja AJ. Advances in the current treatment of autoimmune hepatitis. Dig Dis Sci. 2012;57:1996-2010. [PMID: 22476586 DOI: 10.1007/s10620-012-2151-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
197 Shan J, Stevens KR, Trehan K, Underhill GH, Chen AA, Bhatia SN. Hepatic Tissue Engineering. In: Monga SPS, editor. Molecular Pathology of Liver Diseases. Boston: Springer US; 2011. pp. 321-42. [DOI: 10.1007/978-1-4419-7107-4_22] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
198 Wigg AJ, McCormick R, Wundke R, Woodman RJ. Efficacy of a chronic disease management model for patients with chronic liver failure. Clin Gastroenterol Hepatol. 2013;11:850-858.e1-4. [PMID: 23375997 DOI: 10.1016/j.cgh.2013.01.014] [Cited by in Crossref: 75] [Cited by in F6Publishing: 62] [Article Influence: 8.3] [Reference Citation Analysis]
199 Sharif F, Mohebbi S, Tabatabaee HR, Saberi-Firoozi M, Gholamzadeh S. Effects of psycho-educational intervention on health-related quality of life (QOL) of patients with chronic liver disease referring to Shiraz University of Medical Sciences. Health Qual Life Outcomes. 2005;3:81. [PMID: 16356186 DOI: 10.1186/1477-7525-3-81] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
200 Arteel GE. New role of plasminogen activator inhibitor-1 in alcohol-induced liver injury. J Gastroenterol Hepatol. 2008;23 Suppl 1:S54-S59. [PMID: 18336665 DOI: 10.1111/j.1440-1746.2007.05285.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
201 van Werven J, Schreuder T, Nederveen A, Lavini C, Jansen P, Stoker J. Hepatic unsaturated fatty acids in patients with non-alcoholic fatty liver disease assessed by 3.0T MR spectroscopy. European Journal of Radiology 2010;75:e102-7. [DOI: 10.1016/j.ejrad.2009.12.033] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
202 Yu AS, Keeffe EB. Elevated AST or ALT to nonalcoholic fatty liver disease: accurate predictor of disease prevalence? Am J Gastroenterol 2003;98:955-6. [PMID: 12809814 DOI: 10.1111/j.1572-0241.2003.07485.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 2.9] [Reference Citation Analysis]
203 Dan AA, Martin LM, Crone C, Ong JP, Farmer DW, Wise T, Robbins SC, Younossi ZM. Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol. 2006;44:491-498. [PMID: 16427157 DOI: 10.1016/j.jhep.2005.11.046] [Cited by in Crossref: 95] [Cited by in F6Publishing: 92] [Article Influence: 5.6] [Reference Citation Analysis]
204 Molinari M, Matz J, DeCoutere S, El-Tawil K, Abu-Wasel B, Keough V. Live liver donors' risk thresholds: risking a life to save a life. HPB (Oxford) 2014;16:560-74. [PMID: 24251593 DOI: 10.1111/hpb.12192] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
205 Desai S, Peltekian KM. Canadian mortality rates for liver disease: taking a closer look at ICD coding. Can J Public Health 2004;95:198-200. [PMID: 15191123 [PMID: 15191123 DOI: 10.1007/bf03403648] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
206 Annicchiarico BE, Avolio AW, Siciliano M, Passalacqua S, Caracciolo G, Gasbarrini A, Agnes S, Castagneto M. Acute decompensation and absence of brain and kidney dysfunction predict long-term efficacy of plasma exchange in hyper-bilirubinemic cirrhotic patients awaiting liver transplantation. Transplant Proc 2008;40:1929-31. [PMID: 18675092 DOI: 10.1016/j.transproceed.2008.05.064] [Reference Citation Analysis]
207 Chávez-tapia N, Torres-sánchez J, Romero-flores J, Álvarez-quiroz P, Ramírez-álvarez S, Juárez-hernández E, Pérez-jáuregui J, Méndez-sánchez N, Uribe M. Prevalence in vulnerable population of liver fibrosis identified by transient elastography. Annals of Hepatology 2015;14:524-30. [DOI: 10.1016/s1665-2681(19)31174-3] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
208 Elliott C, Frith J, Day CP, Jones DEJ, Newton JL. Functional Impairment in Alcoholic Liver Disease and Non-alcoholic Fatty Liver Disease Is Significant and Persists over 3 Years of Follow-Up. Dig Dis Sci 2013;58:2383-91. [DOI: 10.1007/s10620-013-2657-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
209 Petitclerc L, Gilbert G, Nguyen BN, Tang A. Liver Fibrosis Quantification by Magnetic Resonance Imaging. Top Magn Reson Imaging 2017;26:229-41. [PMID: 28858038 DOI: 10.1097/RMR.0000000000000149] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
210 Kolachi NF, Kazi TG, Afridi HI, Kazi NG, Khan S. Investigation of essential trace and toxic elements in biological samples (blood, serum and scalp hair) of liver cirrhotic/cancer female patients before and after mineral supplementation. Clinical Nutrition 2012;31:967-73. [DOI: 10.1016/j.clnu.2012.04.015] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
211 Aljawad M, Yoshida EM, Uhanova J, Marotta P, Chandok N. Percutaneous liver biopsy practice patterns among Canadian hepatologists. Can J Gastroenterol 2013;27:e31-4. [PMID: 24199212 DOI: 10.1155/2013/429834] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
212 Moghe A, Yakovchenko V, Morgan T, McCurdy H, Scott D, Rozenberg-Ben-Dror K, Rogal S. Strategies to Improve Delivery of Cirrhosis Care. Curr Treat Options Gastroenterol 2021;:1-11. [PMID: 34054289 DOI: 10.1007/s11938-021-00345-y] [Reference Citation Analysis]
213 Mas V, Maluf D, Archer KJ, Potter A, Suh J, Gehrau R, Descalzi V, Villamil F. Transcriptome at the time of hepatitis C virus recurrence may predict the severity of fibrosis progression after liver transplantation. Liver Transpl 2011;17:824-35. [PMID: 21618696 DOI: 10.1002/lt.22309] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
214 Chacko KR, Reinus J. Spectrum of Alcoholic Liver Disease. Clin Liver Dis 2016;20:419-27. [PMID: 27373606 DOI: 10.1016/j.cld.2016.02.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
215 Noureddin M, Yates KP, Vaughn IA, Neuschwander-Tetri BA, Sanyal AJ, McCullough A, Merriman R, Hameed B, Doo E, Kleiner DE, Behling C, Loomba R; NASH CRN. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology. 2013;58:1644-1654. [PMID: 23686698 DOI: 10.1002/hep.26465] [Cited by in Crossref: 103] [Cited by in F6Publishing: 93] [Article Influence: 11.4] [Reference Citation Analysis]
216 Solomon M, Bonafede M, Pan K, Wilson K, Beam C, Chakravarti P, Spiegel B. Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients. Dig Dis Sci 2011;56:3024-31. [PMID: 21717127 DOI: 10.1007/s10620-011-1802-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
217 Zapolski TC, Pedersen SL, McCarthy DM, Smith GT. Less drinking, yet more problems: understanding African American drinking and related problems. Psychol Bull 2014;140:188-223. [PMID: 23477449 DOI: 10.1037/a0032113] [Cited by in Crossref: 167] [Cited by in F6Publishing: 156] [Article Influence: 18.6] [Reference Citation Analysis]
218 Zhong Z, Lemasters JJ. A Unifying Hypothesis Linking Hepatic Adaptations for Ethanol Metabolism to the Proinflammatory and Profibrotic Events of Alcoholic Liver Disease. Alcohol Clin Exp Res 2018;42:2072-89. [PMID: 30132924 DOI: 10.1111/acer.13877] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
219 Duan BW, Lu SC, Wu JS, Guo QL, Zeng DB, Jiang T, Kong DG, Ding J. Model for End-Stage Liver Disease (MELD) score does not predict outcomes of hepatitis B-induced acute-on-chronic liver failure in transplant recipients. Transplant Proc. 2014;46:3502-3506. [PMID: 25498080 DOI: 10.1016/j.transproceed.2014.07.075] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
220 Bhatia SN, Underhill GH, Zaret KS, Fox IJ. Cell and tissue engineering for liver disease. Sci Transl Med. 2014;6:245sr2. [PMID: 25031271 DOI: 10.1126/scitranslmed.3005975] [Cited by in Crossref: 178] [Cited by in F6Publishing: 167] [Article Influence: 25.4] [Reference Citation Analysis]
221 Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB; NASH CRN Research Group. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 2011;106:460-8; quiz 469. [PMID: 21206486 DOI: 10.1038/ajg.2010.488] [Cited by in Crossref: 238] [Cited by in F6Publishing: 172] [Article Influence: 21.6] [Reference Citation Analysis]
222 Hyde AM, Watt M, Carbonneau M, Eboreime EA, Abraldes JG, Tandon P. Understanding Preferences Toward Virtual Care: A Pre-COVID Mixed Methods Study Exploring the Perspectives of Patients with Chronic Liver Disease. Telemed J E Health 2021. [PMID: 34085869 DOI: 10.1089/tmj.2021.0099] [Reference Citation Analysis]
223 Mas VR, Maluf DG, Archer KJ, Yanek K, Bornstein K, Fisher RA. Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. Transplantation 2009;87:143-52. [PMID: 19136905 DOI: 10.1097/TP.0b013e318191c68d] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
224 Barve A, Khan R, Marsano L, V Ravindra K, Mcclain C. Treatment of alcoholic liver disease. Annals of Hepatology 2008;7:5-15. [DOI: 10.1016/s1665-2681(19)31883-6] [Cited by in Crossref: 27] [Article Influence: 1.9] [Reference Citation Analysis]
225 Koola JD, Davis SE, Al-Nimri O, Parr SK, Fabbri D, Malin BA, Ho SB, Matheny ME. Development of an automated phenotyping algorithm for hepatorenal syndrome. J Biomed Inform 2018;80:87-95. [PMID: 29530803 DOI: 10.1016/j.jbi.2018.03.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
226 Chen P, Torralba M, Tan J, Embree M, Zengler K, Stärkel P, van Pijkeren JP, DePew J, Loomba R, Ho SB. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology. 2015;148:203-214.e16. [PMID: 25239591 DOI: 10.1053/j.gastro.2014.09.014] [Cited by in Crossref: 154] [Cited by in F6Publishing: 153] [Article Influence: 19.3] [Reference Citation Analysis]
227 Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology. 2005;42:255-262. [PMID: 16025497 DOI: 10.1002/hep.20793] [Cited by in Crossref: 288] [Cited by in F6Publishing: 226] [Article Influence: 16.9] [Reference Citation Analysis]
228 Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y, Xuan SY. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53:726-736. [PMID: 21319189 DOI: 10.1002/hep.24105] [Cited by in Crossref: 538] [Cited by in F6Publishing: 499] [Article Influence: 48.9] [Reference Citation Analysis]
229 Larson AM. Palliative Care for Patients with End-Stage Liver Disease. Curr Gastroenterol Rep 2015;17. [DOI: 10.1007/s11894-015-0440-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
230 Oga EF, Sekine S, Shitara Y, Horie T. Pharmacokinetic Herb-Drug Interactions: Insight into Mechanisms and Consequences. Eur J Drug Metab Pharmacokinet 2016;41:93-108. [PMID: 26311243 DOI: 10.1007/s13318-015-0296-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
231 Lee TC, Kaiser TE, Alloway R, Woodle ES, Edwards MJ, Shah SA. Telemedicine Based Remote Home Monitoring After Liver Transplantation: Results of a Randomized Prospective Trial. Ann Surg 2019;270:564-72. [PMID: 31356267 DOI: 10.1097/SLA.0000000000003425] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
232 Sypsa V, Touloumi G, Tassopoulos NC, Ketikoglou I, Vafiadis I, Hatzis G, Tsantoulas D, Akriviadis E, Delladetsima J, Demonakou M. Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. J Viral Hepat. 2004;11:366-374. [PMID: 15230860 DOI: 10.1111/j.1365-2893.2004.00517.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.1] [Reference Citation Analysis]
233 Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasound-Based Transient Elastography for the Detection of Hepatic Fibrosis: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2007;5:1214-20. [DOI: 10.1016/j.cgh.2007.07.020] [Cited by in Crossref: 327] [Cited by in F6Publishing: 305] [Article Influence: 21.8] [Reference Citation Analysis]
234 Petrasek J, Dolganiuc A, Csak T, Nath B, Hritz I, Kodys K, Catalano D, Kurt-Jones E, Mandrekar P, Szabo G. Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells. Hepatology. 2011;53:649-660. [PMID: 21274885 DOI: 10.1002/hep.24059] [Cited by in Crossref: 69] [Cited by in F6Publishing: 74] [Article Influence: 6.3] [Reference Citation Analysis]
235 Ho M, Yu C, Chung K, Chen T, Chu H, Lin C, Hsieh C. Locoregional Therapy-Induced Tumor Necrosis as a Predictor of Recurrence after Liver Transplant in Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2011;18:3632-9. [DOI: 10.1245/s10434-011-1803-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
236 Lim JK, Groszmann RJ. Transient elastography for diagnosis of portal hypertension in liver cirrhosis: is there still a role for hepatic venous pressure gradient measurement? Hepatology. 2007;45:1087-1090. [PMID: 17464984 DOI: 10.1002/hep.21731] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
237 Motzkus-feagans C, Pakyz AL, Ratliff SM, Bajaj JS, Lapane KL. Statin use and infections in Veterans with cirrhosis. Aliment Pharmacol Ther 2013;38:611-8. [DOI: 10.1111/apt.12430] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
238 Asrani SK, O'Leary JG. Acute-on-chronic liver failure. Clin Liver Dis. 2014;18:561-574. [PMID: 25017076 DOI: 10.1016/j.cld.2014.05.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
239 Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, Leblanc M, Coulter S, He M, Scott C, Lau SL, Atkins AR, Barish GD, Gunton JE, Liddle C, Downes M, Evans RM. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell. 2013;153:601-613. [PMID: 23622244 DOI: 10.1016/j.cell.2013.03.028] [Cited by in Crossref: 386] [Cited by in F6Publishing: 389] [Article Influence: 42.9] [Reference Citation Analysis]
240 Saab S, Mallam D, Cox GA 2nd, Tong MJ. Impact of coffee on liver diseases: a systematic review. Liver Int. 2014;34:495-504. [PMID: 24102757 DOI: 10.1111/liv.12304] [Cited by in Crossref: 106] [Cited by in F6Publishing: 90] [Article Influence: 11.8] [Reference Citation Analysis]
241 Salgia RJ, Mullan PB, Mccurdy H, Sales A, Moseley RH, Su GL. The Educational Impact of the Specialty Care Access Network–Extension of Community Healthcare Outcomes Program. Telemedicine and e-Health 2014;20:1004-8. [DOI: 10.1089/tmj.2013.0302] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
242 Vorobioff J, Groszmann R. Portal Hypertension—Molecular Mechanisms. Liver Pathophysiology. Elsevier; 2017. pp. 435-49. [DOI: 10.1016/b978-0-12-804274-8.00034-5] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
243 Yin M, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, Rossman PJ, Fidler JL, Ehman RL. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007;5:1207-1213.e2. [PMID: 17916548 DOI: 10.1016/j.cgh.2007.06.012] [Cited by in Crossref: 640] [Cited by in F6Publishing: 566] [Article Influence: 42.7] [Reference Citation Analysis]
244 Willner IR, Reuben A. Alcohol and the liver. Curr Opin Gastroenterol. 2005;21:323-330. [PMID: 15818153 DOI: 10.1097/01.mog.0000160044.87933.87] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
245 Yeh H, Machaidze Z, Wamala I, Fraser JW, Navarro-Alvarez N, Kim K, Schuetz C, Shi S, Zhu A, Hertl M, Elias N, Farkash EA, Vagefi PA, Varma M, Smith RN, Robson SC, Van Cott EM, Sachs DH, Markmann JF. Increased transfusion-free survival following auxiliary pig liver xenotransplantation. Xenotransplantation. 2014;21:454-464. [PMID: 25130043 DOI: 10.1111/xen.12111] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
246 Piscaglia F, Bolondi L. Recent advances in the diagnosis of hepatocellular carcinoma. Hepatology Research 2007;37:S178-92. [DOI: 10.1111/j.1872-034x.2007.00183.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
247 Guimaraes AR, Siqueira L, Uppal R, Alford J, Fuchs BC, Yamada S, Tanabe K, Chung RT, Lauwers G, Chew ML, Boland GW, Sahani DV, Vangel M, Hahn PF, Caravan P. T2 relaxation time is related to liver fibrosis severity. Quant Imaging Med Surg 2016;6:103-14. [PMID: 27190762 DOI: 10.21037/qims.2016.03.02] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
248 Li WX, Yan X, Shi CR, Zhang AP. Chlorambucil for patients with primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;9:CD008714. [PMID: 22972125 DOI: 10.1002/14651858.cd008714.pub2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
249 Saberi B, Dadabhai AS, Jang YY, Gurakar A, Mezey E. Current Management of Alcoholic Hepatitis and Future Therapies. J Clin Transl Hepatol 2016;4:113-22. [PMID: 27350941 DOI: 10.14218/JCTH.2016.00006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
250 Rockey DC, Friedman SL. Hepatic Fibrosis and Cirrhosis. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 64-85. [DOI: 10.1016/b978-1-4377-0881-3.00005-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
251 Brophy CM, Nyberg SL. Is there a future for the bioartificial liver?: . Current Opinion in Organ Transplantation 2006;11:219-25. [DOI: 10.1097/01.mot.0000227836.98957.be] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
252 Foster T, Anania FA, Li D, Katz R, Budoff M. The prevalence and clinical correlates of nonalcoholic fatty liver disease (NAFLD) in African Americans: the multiethnic study of atherosclerosis (MESA). Dig Dis Sci. 2013;58:2392-2398. [PMID: 23546700 DOI: 10.1007/s10620-013-2652-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
253 Kim W. [Diagnostic and therapeutic strategies for severe alcoholic hepatitis]. Korean J Gastroenterol 2015;65:4-11. [PMID: 25603848 DOI: 10.4166/kjg.2015.65.1.4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
254 Naeem M, Rahimnajjad NA, Rahimnajjad MK, Khurshid M, Ahmed QJ, Shahid SM, Khawar F, Najjar MM. Assessment of characteristics of patients with cholelithiasis from economically deprived rural Karachi, Pakistan. BMC Res Notes. 2012;5:334. [PMID: 22741543 DOI: 10.1186/1756-0500-5-334] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
255 Kim W, Kim DJ. Severe alcoholic hepatitis-current concepts, diagnosis and treatment options. World J Hepatol 2014; 6(10): 688-695 [PMID: 25349640 DOI: 10.4254/wjh.v6.i10.688] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
256 Yin M, Chen J, Glaser KJ, Talwalkar JA, Ehman RL. Abdominal magnetic resonance elastography. Top Magn Reson Imaging. 2009;20:79-87. [PMID: 20010062 DOI: 10.1097/rmr.0b013e3181c4737e] [Cited by in Crossref: 61] [Cited by in F6Publishing: 28] [Article Influence: 5.1] [Reference Citation Analysis]
257 Hamaguchi M, Obora A, Okamura T, Hashimoto Y, Kojima T, Fukui M. Changes in metabolic complications in patients with alcoholic fatty liver disease monitored over two decades: NAGALA study. BMJ Open Gastroenterol 2020;7:e000359. [PMID: 32337056 DOI: 10.1136/bmjgast-2019-000359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
258 Sripa B, Kanla P, Sinawat P, Haswell-Elkins MR. Opisthorchiasis-associated biliary stones: Light and scanning electron microscopic study. World J Gastroenterol 2004; 10(22): 3318-3321 [PMID: 15484308 DOI: 10.3748/wjg.v10.i22.3318] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
259 Ognjanovic S, Yuan JM, Chaptman AK, Fan Y, Yu MC. Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA. Carcinogenesis. 2009;30:758-762. [PMID: 19126646 DOI: 10.1093/carcin/bgn286] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 3.4] [Reference Citation Analysis]
260 Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005;41:790-800. [PMID: 15791608 DOI: 10.1002/hep.20659] [Cited by in Crossref: 263] [Cited by in F6Publishing: 257] [Article Influence: 15.5] [Reference Citation Analysis]
261 Kanwal F. Coordinating care in patients with cirrhosis. Clin Gastroenterol Hepatol. 2013;11:859-861. [PMID: 23542329 DOI: 10.1016/j.cgh.2013.03.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
262 Murray KF, Carithers RL Jr;  AASLD. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology. 2005;41:1407-1432. [PMID: 15880505 DOI: 10.1002/hep.20704] [Cited by in Crossref: 519] [Cited by in F6Publishing: 406] [Article Influence: 30.5] [Reference Citation Analysis]
263 Bergheim I, Guo L, Davis MA, Duveau I, Arteel GE. Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis. J Pharmacol Exp Ther. 2006;316:592-600. [PMID: 16221737 DOI: 10.1124/jpet.105.095042] [Cited by in Crossref: 94] [Cited by in F6Publishing: 90] [Article Influence: 5.5] [Reference Citation Analysis]
264 El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126:460-468. [PMID: 14762783 DOI: 10.1053/j.gastro.2003.10.065] [Cited by in Crossref: 788] [Cited by in F6Publishing: 687] [Article Influence: 43.8] [Reference Citation Analysis]
265 Talwalkar JA. Functional hepatic imaging and disease recurrence after liver transplantation. Liver Transpl 2006;12:1744-6. [DOI: 10.1002/lt.20891] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
266 Paula H, Asrani SK, Boetticher NC, Pedersen R, Shah VH, Kim WR. Alcoholic liver disease-related mortality in the United States: 1980-2003. Am J Gastroenterol. 2010;105:1782-1787. [PMID: 20179691 DOI: 10.1038/ajg.2010.46] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 4.5] [Reference Citation Analysis]
267 Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl. 2003;9:S28-S34. [PMID: 14586892 DOI: 10.1053/jlts.2003.50248] [Cited by in Crossref: 170] [Cited by in F6Publishing: 153] [Article Influence: 9.4] [Reference Citation Analysis]
268 Kramer JR, Puenpatom A, Erickson KF, Cao Y, Smith D, El-Serag HB, Kanwal F. Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system. J Viral Hepat 2018;25:1270-9. [PMID: 29851265 DOI: 10.1111/jvh.12937] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
269 Nader LA, de Mattos AA, Bastos GA. Burden of liver disease in Brazil. Liver Int. 2014;34:844-849. [PMID: 24422599 DOI: 10.1111/liv.12470] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
270 Junaidi O, Di Bisceglie AM. Aging liver and hepatitis. Clin Geriatr Med 2007;23:889-903, viii. [PMID: 17923344 DOI: 10.1016/j.cger.2007.06.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
271 Choi G, Runyon BA. Alcoholic Hepatitis: A Clinician’s Guide. Clinics in Liver Disease 2012;16:371-85. [DOI: 10.1016/j.cld.2012.03.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
272 Vigani AG, Gonçales ES, Postal Pavan MH, Genari F, Tozzo R, Kroll Lazarini MS, Fais V, Feltrin A, Gonçales NS, Gonçales FL. Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3. The Brazilian Journal of Infectious Diseases 2012;16:232-6. [DOI: 10.1016/s1413-8670(12)70316-1] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
273 Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut. 2006;55 Suppl 6:vi1-v12. [PMID: 16966752 DOI: 10.1136/gut.2006.099580] [Cited by in Crossref: 153] [Cited by in F6Publishing: 151] [Article Influence: 10.2] [Reference Citation Analysis]
274 Carpentier S, Bhat M, Deschenes M, Wong P, Ghali P, Sebastiani G. A care coordination program to optimize management of cirrhosis: real-life applicability and feasibility in the context of the Canadian health care system. Can J Gastroenterol Hepatol 2014;28:221-2. [PMID: 24729998 DOI: 10.1155/2014/726409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
275 Lee YY, Kim SW, Youn SH, Hyun SH, Kyung JS, In G, Park CK, Jung HR, Moon SJ, Kang MJ, Yi EC, Han CK. Biological Effects of Korean Red Ginseng Polysaccharides in Aged Rat Using Global Proteomic Approach. Molecules 2020;25:E3019. [PMID: 32630349 DOI: 10.3390/molecules25133019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
276 Yang M, Xu D, Liu Y, Guo X, Li W, Guo C, Zhang H, Gao Y, Mao Y, Zhao J. Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis. PLoS One. 2015;10:e0131664. [PMID: 26121037 DOI: 10.1371/journal.pone.0131664] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
277 Deitelzweig S, Amin A, Christian R, Friend K, Lin J, Lowe TJ. Hyponatremia-associated healthcare burden among US patients hospitalized for cirrhosis. Adv Ther 2013;30:71-80. [PMID: 23292659 DOI: 10.1007/s12325-012-0073-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
278 Zhang B, Li Y, Wang G, Jia Z, Li H, Peng Q, Gao Y. Fabrication of agarose concave petridish for 3D-culture microarray method for spheroids formation of hepatic cells. J Mater Sci: Mater Med 2018;29. [DOI: 10.1007/s10856-018-6058-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
279 Kartoun U, Corey KE, Simon TG, Zheng H, Aggarwal R, Ng K, Shaw SY. The MELD-Plus: A generalizable prediction risk score in cirrhosis. PLoS One. 2017;12:e0186301. [PMID: 29069090 DOI: 10.1371/journal.pone.0186301] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
280 Pandey P, Pandey A, Dillhoff M, Schmidt C, Kamel IR, Pawlik TM. Assessing the Non-tumorous Liver: Implications for Patient Management and Surgical Therapy. J Gastrointest Surg 2018;22:344-60. [PMID: 28924922 DOI: 10.1007/s11605-017-3562-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
281 Lim Y, Kim WR. The Global Impact of Hepatic Fibrosis and End-Stage Liver Disease. Clinics in Liver Disease 2008;12:733-46. [DOI: 10.1016/j.cld.2008.07.007] [Cited by in Crossref: 187] [Cited by in F6Publishing: 176] [Article Influence: 13.4] [Reference Citation Analysis]
282 Buckwold VE, Wei J, Wenzel-Mathers M, Russell J. Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication. Antimicrob Agents Chemother 2003;47:2293-8. [PMID: 12821481 DOI: 10.1128/AAC.47.7.2293-2298.2003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
283 Khan R, Ravi S, Chirapongsathorn S, Jennings W, Salameh H, Russ K, Skinner M, Mudumbi S, Simonetto D, Kuo YF, Kamath PS, Singal AK. Model for End-Stage Liver Disease Score Predicts Development of First Episode of Spontaneous Bacterial Peritonitis in Patients With Cirrhosis. Mayo Clin Proc 2019;94:1799-806. [PMID: 31400909 DOI: 10.1016/j.mayocp.2019.02.027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
284 Gonzalez SA, Fiel MI, Sauk J, Canchis PW, Liu RC, Chiriboga L, Yee HT, Jacobson IM, Talal AH. Inverse association between hepatic stellate cell apoptosis and fibrosis in chronic hepatitis C virus infection. J Viral Hepat 2009;16:141-8. [PMID: 19175868 DOI: 10.1111/j.1365-2893.2008.01052.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
285 Roebuck B. Hyperplasia, partial hepatectomy, and the carcinogenicity of aflatoxin B1. J Cell Biochem 2004;91:243-9. [DOI: 10.1002/jcb.10758] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
286 Wei J, Shi M, Wu WQ, Xu H, Wang T, Wang N, Ma JL, Wang YG. IκB kinase-beta inhibitor attenuates hepatic fibrosis in mice. World J Gastroenterol 2011; 17(47): 5203-5213 [PMID: 22215946 DOI: 10.3748/wjg.v17.i47.5203] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
287 Mohammad MK, Zhou Z, Cave M, Barve A, McClain CJ. Zinc and liver disease. Nutr Clin Pract. 2012;27:8-20. [PMID: 22307488 DOI: 10.1177/0884533611433534] [Cited by in Crossref: 116] [Cited by in F6Publishing: 93] [Article Influence: 11.6] [Reference Citation Analysis]
288 Ghalib R, Levine C, Hassan M, McClelland T, Goss J, Stribling R, Seu P, Patt YZ. Recombinant human interleukin-11 improves thrombocytopenia in patients with cirrhosis. Hepatology. 2003;37:1165-1171. [PMID: 12717398 DOI: 10.1053/jhep.2003.50160] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
289 Bajaj JS, Ratliff SM, Heuman DM, Lapane KL. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther. 2012;36:866-874. [PMID: 22966967 DOI: 10.1111/apt.12045] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 7.2] [Reference Citation Analysis]
290 Natarajan Y, Kanwal F. Pay for Performance in Chronic Liver Disease. Clin Gastroenterol Hepatol 2015;13:2042-7. [PMID: 26164221 DOI: 10.1016/j.cgh.2015.06.038] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
291 Nguyen AL, Park H, Nguyen P, Sheen E, Kim YA, Nguyen MH. Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA. Dig Dis Sci 2019;64:698-707. [DOI: 10.1007/s10620-018-5326-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
292 Shah NL, Northup PG, Caldwell SH. A clinical survey of bleeding, thrombosis, and blood product use in decompensated cirrhosis patients. Annals of Hepatology 2012;11:686-90. [DOI: 10.1016/s1665-2681(19)31443-7] [Cited by in Crossref: 41] [Article Influence: 4.1] [Reference Citation Analysis]
293 Kanwal F, Kramer J, Asch SM, El-Serag H, Spiegel BM, Edmundowicz S, Sanyal AJ, Dominitz JA, McQuaid KR, Martin P, Keeffe EB, Friedman LS, Ho SB, Durazo F, Bacon BR. An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol. 2010;8:709-717. [PMID: 20385251 DOI: 10.1016/j.cgh.2010.03.028] [Cited by in Crossref: 91] [Cited by in F6Publishing: 81] [Article Influence: 7.6] [Reference Citation Analysis]
294 Akinbami AA, Oshinaike OO, Dosunmu OA, Adeyemo TA, Adediran A, Akanmu S, Wright KO, Ilori S, Aile K. Seroprevalence of hepatitis B e antigen (HBe antigen) and B core antibodies (IgG anti-HBcore and IgM anti-HBcore) among hepatitis B surface antigen positive blood donors at a Tertiary Centre in Nigeria. BMC Res Notes 2012;5:167. [PMID: 22455501 DOI: 10.1186/1756-0500-5-167] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
295 Wei X, Ma Y, Dong Z, Wang G, Lan X, Liao Z, Chen M. Dehydrodiconiferyl alcohol, a lignan from Herpetospermum pedunculosum, alleviates cholestasis by activating pathways associated with the farnesoid X receptor. Phytomedicine 2021;80:153378. [PMID: 33113499 DOI: 10.1016/j.phymed.2020.153378] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
296 Ridola L, Nardelli S, Gioia S, Riggio O. Quality of life in patients with minimal hepatic encephalopathy. World J Gastroenterol 2018; 24(48): 5446-5453 [PMID: 30622374 DOI: 10.3748/wjg.v24.i48.5446] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
297 Takikawa Y, Endo R, Suzuki K, Fujiwara K, Omata M. Prediction of hepatic encephalopathy development in patients with severe acute hepatitis. Dig Dis Sci. 2006;51:359-364. [PMID: 16534681 DOI: 10.1007/s10620-006-3138-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
298 Barboza KC, Salinas LM, Sahebjam F, Jesudian AB, Weisberg IL, Sigal SH. Impact of depressive symptoms and hepatic encephalopathy on health-related quality of life in cirrhotic hepatitis C patients. Metab Brain Dis 2016;31:869-80. [DOI: 10.1007/s11011-016-9817-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
299 Kim W. [Treatment Options in Non-alcoholic Fatty Liver Disease]. Korean J Gastroenterol 2017;69:353-8. [PMID: 28637104 DOI: 10.4166/kjg.2017.69.6.353] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
300 Goldsmith JR, Jobin C. Think small: zebrafish as a model system of human pathology. J Biomed Biotechnol. 2012;2012:817341. [PMID: 22701308 DOI: 10.1155/2012/817341] [Cited by in Crossref: 84] [Cited by in F6Publishing: 91] [Article Influence: 8.4] [Reference Citation Analysis]
301 Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Heuman D, Coterrell A, Fisher RA, Contos MJ, Mills AS. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006;43:682-9. [DOI: 10.1002/hep.21103] [Cited by in Crossref: 345] [Cited by in F6Publishing: 308] [Article Influence: 21.6] [Reference Citation Analysis]
302 Long L, Li H, Deng G, Wang X, Lu S, Li B, Meng Z, Gao Y, Qian Z, Liu F, Lu X, Ren H, Shang J, Li H, Wang S, Zheng Y, Yan H, Yin S, Tan W, Zhang Q, Zheng X, Chen J, Luo S, Zhao J, Yuan W, Li T, Zheng R, Liu J, Liu X, Gu W, Li S, Mei X, Chen R, Huang Y. Impact of Hepatic Encephalopathy on Clinical Characteristics and Adverse Outcomes in Prospective and Multicenter Cohorts of Patients With Acute-on-Chronic Liver Diseases. Front Med (Lausanne) 2021;8:709884. [PMID: 34409052 DOI: 10.3389/fmed.2021.709884] [Reference Citation Analysis]
303 Park JY, Han J, Jung HS, Lee G, Kim HJ, Cho G, Park H, Han C, Kim JS, Kim J. Synthetic probes for in vitro purification and in vivo tracking of hepatocytes derived from human pluripotent stem cells. Biomaterials 2019;222:119431. [DOI: 10.1016/j.biomaterials.2019.119431] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
304 Kanwal F, Hoang T, Spiegel BM, Eisen S, Dominitz JA, Gifford A, Goetz M, Asch SM. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology. 2007;46:1741-1749. [PMID: 18046707 DOI: 10.1002/hep.21927] [Cited by in Crossref: 94] [Cited by in F6Publishing: 92] [Article Influence: 6.7] [Reference Citation Analysis]
305 Bajaj JS, Reddy KR, O'Leary JG, Vargas HE, Lai JC, Kamath PS, Tandon P, Wong F, Subramanian RM, Thuluvath P, Fagan A, White MB, Gavis EA, Sehrawat T, de la Rosa Rodriguez R, Thacker LR, Sikaroodi M, Garcia-Tsao G, Gillevet PM. Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With Cirrhosis. Gastroenterology 2020;159:1715-1730.e12. [PMID: 32687928 DOI: 10.1053/j.gastro.2020.07.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
306 Kanwal F, Hoang T, Chrusciel T, Kramer JR, El-serag HB, Durfee J, Dominitz JA, Yano EM, Asch SM. Association Between Facility Characteristics and the Process of Care Delivered to Patients with Hepatitis C Virus Infection. Dig Dis Sci 2014;59:273-81. [DOI: 10.1007/s10620-013-2773-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
307 Han MA, Saouaf R, Ayoub W, Todo T, Mena E, Noureddin M. Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD). Expert Rev Clin Pharmacol. 2017;10:379-390. [PMID: 28277807 DOI: 10.1080/17512433.2017.1299573] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
308 Buckwold VE, Beer BE, Donis RO. Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents. Antiviral Res 2003;60:1-15. [PMID: 14516916 DOI: 10.1016/s0166-3542(03)00174-8] [Cited by in Crossref: 95] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
309 Guerrerio AL, Colvin RM, Schwartz AK, Molleston JP, Murray KF, Diehl A, Mohan P, Schwimmer JB, Lavine JE, Torbenson MS. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr. 2012;95:892-900. [PMID: 22338037 DOI: 10.3945/ajcn.111.020156] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 6.9] [Reference Citation Analysis]
310 Mohammadi S, Nezami A, Esmaeili Z, Rouini MR, Ardakani YH, Lavasani H, Hassanzadeh G, Ghazi-khansari M. Pharmacokinetic changes of tramadol in rats with hepatotoxicity induced by ethanol and acetaminophen in perfused rat liver model. Alcohol 2019;77:49-57. [DOI: 10.1016/j.alcohol.2018.09.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
311 Noureddin M, Lam J, Peterson MR, Middleton M, Hamilton G, Le TA, Bettencourt R, Changchien C, Brenner DA, Sirlin C. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013;58:1930-1940. [PMID: 23696515 DOI: 10.1002/hep.26455] [Cited by in Crossref: 286] [Cited by in F6Publishing: 257] [Article Influence: 31.8] [Reference Citation Analysis]
312 Brunt EM, Tiniakos DG. Steatosis, steatohepatitis: Review of effects on chronic hepatitis C. Current Hepatitis Reports 2002;1:38-44. [DOI: 10.1007/s11901-002-0007-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
313 Brazzelli M, Cruickshank M, Kilonzo M, Ahmed I, Stewart F, McNamee P, Elders A, Fraser C, Avenell A, Ramsay C. Clinical effectiveness and cost-effectiveness of cholecystectomy compared with observation/conservative management for preventing recurrent symptoms and complications in adults presenting with uncomplicated symptomatic gallstones or cholecystitis: a systematic review and economic evaluation. Health Technol Assess 2014;18:1-101, v-vi. [PMID: 25164349 DOI: 10.3310/hta18550] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
314 Chien CF, Wu YT, Tsai TH. Biological analysis of herbal medicines used for the treatment of liver diseases. Biomed Chromatogr 2011;25:21-38. [PMID: 21204110 DOI: 10.1002/bmc.1568] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
315 Basra S, Anand BS. Definition, epidemiology and magnitude of alcoholic hepatitis. World J Hepatol 2011; 3(5): 108-113 [PMID: 21731902 DOI: 10.4254/wjh.v3.i5.108] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 4.4] [Reference Citation Analysis]
316 Buzzetti E, Parikh PM, Gerussi A, Tsochatzis E. Gender differences in liver disease and the drug-dose gender gap. Pharmacol Res 2017;120:97-108. [PMID: 28336373 DOI: 10.1016/j.phrs.2017.03.014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
317 Beier JI, Arteel GE. Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism. Exp Biol Med (Maywood) 2012;237:1-9. [PMID: 22238286 DOI: 10.1258/ebm.2011.011255] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
318 Urrunaga NH, Rachakonda VP, Magder LS, Mindikoglu AL. Outcomes of living versus deceased donor liver transplantation for acute liver failure in the United States. Transplant Proc. 2014;46:219-224. [PMID: 24507055 DOI: 10.1016/j.transproceed.2013.08.111] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
319 Volk ML, Piette JD, Singal AS, Lok AS. Chronic disease management for patients with cirrhosis. Gastroenterology. 2010;139:14-16.e1. [PMID: 20553725 DOI: 10.1053/j.gastro.2010.05.017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
320 Burra P, Belli L, Fagiuoli S, Angelico M, Costa AN, Caraceni P, Toniutto P. Skills and requirements of a transplant hepatologist: board certification of the Italian Association for the Study of the Liver (AISF). Dig Liver Dis 2013;45:992-4. [PMID: 23816698 DOI: 10.1016/j.dld.2013.04.014] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
321 Sekimoto M, Takada T, Kawarada Y, Nimura Y, Yoshida M, Mayumi T, Miura F, Wada K, Hirota M, Yamashita Y, Strasberg S, Pitt HA, Belghiti J, de Santibanes E, Gadacz TR, Hilvano SC, Kim SW, Liau KH, Fan ST, Belli G, Sachakul V. Need for criteria for the diagnosis and severity assessment of acute cholangitis and cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg 2007;14:11-4. [PMID: 17252292 DOI: 10.1007/s00534-006-1151-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
322 Hauff P, Gottwald U, Ocker M. Early to Phase II drugs currently under investigation for the treatment of liver fibrosis. Expert Opin Investig Drugs. 2015;24:309-327. [PMID: 25547844 DOI: 10.1517/13543784.2015.997874] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
323 Canbay A, Guicciardi ME, Higuchi H, Feldstein A, Bronk SF, Rydzewski R, Taniai M, Gores GJ. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest. 2003;112:152-159. [PMID: 12865404 DOI: 10.1172/jci200317740] [Cited by in Crossref: 159] [Cited by in F6Publishing: 2] [Article Influence: 8.4] [Reference Citation Analysis]
324 Hoodeshenas S, Yin M, Venkatesh SK. Magnetic Resonance Elastography of Liver: Current Update. Top Magn Reson Imaging. 2018;27:319-333. [PMID: 30289828 DOI: 10.1097/rmr.0000000000000177] [Cited by in Crossref: 39] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
325 Martel-Laferrière V, Homberger C, Bichoupan K, Dieterich DT. MELD score and antibiotics use are predictors of length of stay in patients hospitalized with hepatic encephalopathy. BMC Gastroenterol 2014;14:185. [PMID: 25326084 DOI: 10.1186/1471-230X-14-185] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
326 Sass DA, Shaikh OS. Alcoholic Hepatitis. Clinics in Liver Disease 2006;10:219-37. [DOI: 10.1016/j.cld.2006.05.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
327 Mengshol JA, Golden-Mason L, Arikawa T, Smith M, Niki T, McWilliams R, Randall JA, McMahan R, Zimmerman MA, Rangachari M. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One. 2010;5:e9504. [PMID: 20209097 DOI: 10.1371/journal.pone.0] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
328 Mahmoud AM, Hozayen WG, Hasan IH, Shaban E, Bin-Jumah M. Umbelliferone Ameliorates CCl4-Induced Liver Fibrosis in Rats by Upregulating PPARγ and Attenuating Oxidative Stress, Inflammation, and TGF-β1/Smad3 Signaling. Inflammation 2019;42:1103-16. [PMID: 30741365 DOI: 10.1007/s10753-019-00973-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
329 Aggarwal A, Puri K, Liangpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhotic patients: Systematic review. World J Gastroenterol 2014; 20(19): 5737-5745 [PMID: 24914335 DOI: 10.3748/wjg.v20.i19.5737] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
330 Dhiman A, Nanda A, Ahmad S. A quest for staunch effects of flavonoids: Utopian protection against hepatic ailments. Arabian Journal of Chemistry 2016;9:S1813-23. [DOI: 10.1016/j.arabjc.2012.05.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
331 Di Bisceglie AM, Richart JM. Spontaneous retroperitoneal and rectus muscle hemorrhage as a potentially lethal complication of cirrhosis. Liver Int 2006;26:1291-3. [PMID: 17105596 DOI: 10.1111/j.1478-3231.2006.01368.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
332 Durante-Mangoni E, Iardino P, Resse M, Cesaro G, Sica A, Farzati B, Ruggiero G, Adinolfi LE. Silent celiac disease in chronic hepatitis C: impact of interferon treatment on the disease onset and clinical outcome. J Clin Gastroenterol. 2004;38:901-905. [PMID: 15492610 DOI: 10.1097/00004836-200411000-00014] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
333 Czul F, Bhamidimarri KR. Noninvasive Markers to Assess Liver Fibrosis. J Clin Gastroenterol 2016;50:445-57. [PMID: 27105176 DOI: 10.1097/MCG.0000000000000534] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
334 Aloman C, Wands JR. Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy. Hepatology. 2003;38:1584-1587. [PMID: 14655682 DOI: 10.1002/hep.510380633] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
335 Abdel Salam OM, Sleem AA, Shafee N. Hepatoprotective effects of the nitric oxide donor isosorbide-5-mononitrate alone and in combination with the natural hepatoprotectant, silymarin, on carbon tetrachloride-induced hepatic injury in rats. Inflammopharmacology 2010;18:87-94. [PMID: 20069380 DOI: 10.1007/s10787-009-0027-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
336 Aby ES, Pham NV, Yum JJ, Dong TS, Ghasham H, Bedier F, Malley C, Schaenman J, Saab S. Frailty Does Not Impact Caregiver Burden in Patients with Cirrhosis. Dig Dis Sci 2021;66:3343-51. [PMID: 33136228 DOI: 10.1007/s10620-020-06687-4] [Reference Citation Analysis]
337 Zhou G, Zhao J, Ding X, Pan D, Sun Y, Yang J, Zhao Y. Pathological study of 130 cases of nonalcoholic fatty liver disease based on NASH-CRN system. Front Med China 2007;1:413-7. [PMID: 24573937 DOI: 10.1007/s11684-007-0081-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
338 Stickel F, Schuppan D. Herbal medicine in the treatment of liver diseases. Dig Liver Dis. 2007;39:293-304. [PMID: 17331820 DOI: 10.1016/j.dld.2006.11.004] [Cited by in Crossref: 200] [Cited by in F6Publishing: 173] [Article Influence: 13.3] [Reference Citation Analysis]
339 Yamada M, Shiroeda H, Hayashi R, Yano H, Sato K, Tsutsumi M, Arisawa T. Survival rates of early-stage HCV-related liver cirrhosis patients without hepatocellular carcinoma are decreased by alcohol. J Clin Biochem Nutr 2011;48:167-9. [PMID: 21373271 DOI: 10.3164/jcbn.09-119GFR] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
340 Rosso N, Chavez-Tapia NC, Tiribelli C, Bellentani S. Translational approaches: From fatty liver to non-alcoholic steatohepatitis. World J Gastroenterol 2014; 20(27): 9038-9049 [PMID: 25083077 DOI: 10.3748/wjg.v20.i27.9038] [Cited by in F6Publishing: 24] [Reference Citation Analysis]
341 Weston SR, Leyden W, Murphy R, Bass NM, Bell BP, Manos MM, Terrault NA. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology. 2005;41:372-379. [PMID: 15723436 DOI: 10.1002/hep.20554] [Cited by in Crossref: 244] [Cited by in F6Publishing: 227] [Article Influence: 14.4] [Reference Citation Analysis]
342 Sanyal AJ; Governing Board the Public Policy, Clinical Practice, Manpower committees of the AASLD. The Institute of Medicine report on viral hepatitis: a call to action. Hepatology 2010;51:727-8. [PMID: 20198626 DOI: 10.1002/hep.23583] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
343 Tao N, Sussman S, Nieto J, Tsukamoto H, Yuan JM. Demographic characteristics of hospitalized patients with alcoholic liver disease and pancreatitis in los angeles county. Alcohol Clin Exp Res. 2003;27:1798-1804. [PMID: 14634496 DOI: 10.1097/01.alc.0000095862.30777.d9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
344 Bajaj JS. Defining acute-on-chronic liver failure: will East and West ever meet? Gastroenterology. 2013;144:1337-1339. [PMID: 23623966 DOI: 10.1053/j.gastro.2013.04.024] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 6.4] [Reference Citation Analysis]
345 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of alcoholic liver disease. Clin Mol Hepatol. 2013;19:216-254. [PMID: 24133661 DOI: 10.3350/cmh.2013.19.3.216] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
346 Davis GL, Roberts WL. The Healthcare Burden Imposed by Liver Disease in Aging Baby Boomers. Curr Gastroenterol Rep 2010;12:1-6. [DOI: 10.1007/s11894-009-0087-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
347 Richter SS. Laboratory assays for diagnosis and management of hepatitis C virus infection. J Clin Microbiol. 2002;40:4407-4412. [PMID: 12454127 DOI: 10.1128/jcm.40.12.4407-4412.2002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
348 Nabi G, Hao Y, Zeng X, Jinsong Z, McLaughlin RW, Wang D. Hematologic and biochemical differences between two free ranging Yangtze finless porpoise populations: The implications of habitat. PLoS One 2017;12:e0188570. [PMID: 29190288 DOI: 10.1371/journal.pone.0188570] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
349 Sheu MJ, Liang FW, Lin CY, Lu TH. Changes in liver-related mortality by etiology and sequelae: underlying versus multiple causes of death. Popul Health Metr 2021;19:22. [PMID: 33926463 DOI: 10.1186/s12963-021-00249-0] [Reference Citation Analysis]
350 Maluf DG, Archer KJ, Villamil F, Stravitz RT, Mas V. Hepatitis C virus recurrence after liver transplantation: biomarkers of disease and fibrosis progression. Expert Review of Gastroenterology & Hepatology 2014;4:445-58. [DOI: 10.1586/egh.10.39] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
351 Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC; Public Policy Committee of the American Association for the Study of Liver Disease. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008;47:1363-70. [PMID: 18366115 DOI: 10.1002/hep.22109] [Cited by in Crossref: 431] [Cited by in F6Publishing: 390] [Article Influence: 30.8] [Reference Citation Analysis]
352 Ma M, Duan R, Zhong H, Liang T, Guo L. The Crosstalk between Fat Homeostasis and Liver Regional Immunity in NAFLD. J Immunol Res 2019;2019:3954890. [PMID: 30719457 DOI: 10.1155/2019/3954890] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
353 Leslie T, Pawloski L, Kallman-price J, Escheik C, Hossain N, Fang Y, Gerber LH, Younossi ZM. Survey of health status, nutrition and geography of food selection of chronic liver disease patients. Annals of Hepatology 2014;13:533-40. [DOI: 10.1016/s1665-2681(19)31253-0] [Cited by in Crossref: 12] [Article Influence: 1.5] [Reference Citation Analysis]
354 Onishi Y, Wakita T, Fukuhara S, Noguchi Y, Okada M, Sakaida I, Sasaki Y, Kobayashi K. Development and Validation of a Symptom Scale Specific for Ascites Accompanied with Cirrhosis: The ASI-7. Clin Transl Gastroenterol 2014;5:e48. [PMID: 24500340 DOI: 10.1038/ctg.2013.20] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
355 Hartmann P, Chen P, Wang HJ, Wang L, McCole DF, Brandl K, Stärkel P, Belzer C, Hellerbrand C, Tsukamoto H, Ho SB, Schnabl B. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology 2013;58:108-19. [PMID: 23408358 DOI: 10.1002/hep.26321] [Cited by in Crossref: 135] [Cited by in F6Publishing: 127] [Article Influence: 15.0] [Reference Citation Analysis]
356 Shouval D. Focus. J Hepatol 2013;59:201-2. [PMID: 23707442 DOI: 10.1016/j.jhep.2013.05.013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
357 Kennedy P, Wagner M, Castéra L, Hong CW, Johnson CL, Sirlin CB, Taouli B. Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions. Radiology 2018;286:738-63. [PMID: 29461949 DOI: 10.1148/radiol.2018170601] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 29.8] [Reference Citation Analysis]
358 O'Shea RS, McCullough AJ. Treatment of alcoholic hepatitis. Clin Liver Dis 2005;9:103-34. [PMID: 15763232 DOI: 10.1016/j.cld.2004.11.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
359 Gehrau R, Mas V, Archer KJ, Maluf D. Molecular classification and clonal differentiation of hepatocellular carcinoma: the step forward for patient selection for liver transplantation. Expert Rev Gastroenterol Hepatol. 2011;5:539-552. [PMID: 21780900 DOI: 10.1586/egh.11.48] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
360 Volk ML, Tocco RS, Bazick J, Rakoski MO, Lok AS. Hospital readmissions among patients with decompensated cirrhosis. Am J Gastroenterol. 2012;107:247-252. [PMID: 21931378 DOI: 10.1038/ajg.2011.314] [Cited by in Crossref: 266] [Cited by in F6Publishing: 242] [Article Influence: 24.2] [Reference Citation Analysis]
361 Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, Bortey E, Forbes WP. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2011;34:853-861. [PMID: 21848797 DOI: 10.1111/j.1365-2036.2011.04808.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 78] [Article Influence: 8.3] [Reference Citation Analysis]
362 Doganay L, Fejzullahu A, Katrinli S, Enc FY, Ozturk O, Colak Y, Ulasoglu C, Tuncer I, Doganay GD. Association of human leukocyte antigen DQB1 and DRB1 alleles with chronic hepatitis B. World J Gastroenterol 2014; 20(25): 8179-8186 [PMID: 25009391 DOI: 10.3748/wjg.v20.i25.8179] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
363 Passeri MJ, Cinaroglu A, Gao C, Sadler KC. Hepatic steatosis in response to acute alcohol exposure in zebrafish requires sterol regulatory element binding protein activation. Hepatology. 2009;49:443-452. [PMID: 19127516 DOI: 10.1002/hep.22667] [Cited by in Crossref: 131] [Cited by in F6Publishing: 131] [Article Influence: 10.1] [Reference Citation Analysis]
364 Marcos M, Gómez-Munuera M, Pastor I, González-Sarmiento R, Laso FJ. Tumor necrosis factor polymorphisms and alcoholic liver disease: a HuGE review and meta-analysis. Am J Epidemiol 2009;170:948-56. [PMID: 19755636 DOI: 10.1093/aje/kwp236] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
365 Bañares R, Catalina MV, Vaquero J. Liver support systems: will they ever reach prime time? Curr Gastroenterol Rep 2013;15:312. [PMID: 23392862 DOI: 10.1007/s11894-013-0312-x] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
366 Myers RP, Hubbard JN, Shaheen AAM, Dixon E, Kaplan GG. Hospital performance reports based on severity adjusted mortality rates in patients with cirrhosis depend on the method of risk adjustment. Annals of Hepatology 2012;11:526-35. [DOI: 10.1016/s1665-2681(19)31467-x] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]
367 Chavda SJ, Bloom SL. Ascites. Br J Hosp Med (Lond) 2015;76:C23-7. [PMID: 25671486 DOI: 10.12968/hmed.2015.76.2.C23] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
368 Abravaya K, Huff J, Marshall R, Merchant B, Mullen C, Schneider G, Robinson J. Molecular beacons as diagnostic tools: technology and applications. Clin Chem Lab Med. 2003;41:468-474. [PMID: 12747588 DOI: 10.1515/cclm.2003.070] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
369 Nielsen J, Christensen VB, Borgwardt L, Rasmussen A, Østrup O, Kjær MS. Prognostic molecular markers in pediatric liver disease – Are there any? Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2019;1865:577-86. [DOI: 10.1016/j.bbadis.2018.12.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
370 Selmi C, Podda M, Gershwin ME. Old and rising stars in the lymphoid liver. Semin Immunopathol 2009;31:279-82. [PMID: 19603169 DOI: 10.1007/s00281-009-0175-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
371 Shimamura T, Fujisawa T, Husain SR, Kioi M, Nakajima A, Puri RK. Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model. J Immunol 2008;181:4656-65. [PMID: 18802068 DOI: 10.4049/jimmunol.181.7.4656] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 3.7] [Reference Citation Analysis]
372 Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, Brosgart CL. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009;137:1680-1686. [PMID: 19632234 DOI: 10.1053/j.gastro.2009.07.047] [Cited by in Crossref: 125] [Cited by in F6Publishing: 94] [Article Influence: 9.6] [Reference Citation Analysis]
373 Elnagdy M, Barve S, McClain C, Gobejishvili L. cAMP Signaling in Pathobiology of Alcohol Associated Liver Disease. Biomolecules 2020;10:E1433. [PMID: 33050657 DOI: 10.3390/biom10101433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
374 Sebastiani G, Ghali P, Wong P, Klein MB, Deschenes M, Myers RP. Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey. Can J Gastroenterol Hepatol 2014;28:23-30. [PMID: 24416739 DOI: 10.1155/2014/675409] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
375 Dolganiuc A. Role of lipid rafts in liver health and disease. World J Gastroenterol 2011; 17(20): 2520-2535 [PMID: 21633657 DOI: 10.3748/wjg.v17.i20.2520] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
376 Carbonneau M, Eboreime EA, Hyde A, Campbell-scherer D, Faris P, Gramlich L, Tsuyuki RT, Congly SE, Shaheen AA, Sadler M, Zeman M, Spiers J, Abraldes JG, Sugars B, Sia W, Green L, Abdellatif D, Schaefer JP, Selvarajah V, Marr K, Ryan D, Westra Y, Bakshi N, Varghese JC, Tandon P. The cirrhosis care Alberta (CCAB) protocol: implementing an evidence-based best practice order set for the management of liver cirrhosis - a hybrid type I effectiveness-implementation trial. BMC Health Serv Res 2020;20. [DOI: 10.1186/s12913-020-05427-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
377 Park TY, Hong M, Sung H, Kim S, Suk KT. Effect of Korean Red Ginseng in chronic liver disease. J Ginseng Res 2017;41:450-5. [PMID: 29021690 DOI: 10.1016/j.jgr.2016.11.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]